10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________________________________________ 

Form 10-Q

__________________________________________________________ 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2015

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _______ TO _______

Commission file number: 1-10864

__________________________________________________________ 

UnitedHealth Group Incorporated

(Exact name of registrant as specified in its charter)

 __________________________________________________________ 

Delaware	41-1321939
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
UnitedHealth Group Center 9900 Bren Road East Minnetonka, Minnesota	55343
(Address of principal executive offices)	(Zip Code)

(952) 936-1300

(Registrant’s telephone number, including area code)

__________________________________________________________  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes o No x

As of July 24, 2015, there were 953,562,580 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

UNITEDHEALTH GROUP

Table of Contents

			Page
Part I. Financial Information
Item 1.	Financial Statements (unaudited)		1
	Condensed Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014		1
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2015 and 2014		2
	Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2015 and 2014		3
	Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Six Months Ended June 30, 2015 and 2014		4
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2015 and 2014		5
	Notes to the Condensed Consolidated Financial Statements		6
	1.	Basis of Presentation	6
	2.	Investments	7
	3.	Fair Value	9
	4.	Medicare Part D Pharmacy Benefits	13
	5.	Medical Costs Reserve Development	13
	6.	Health Insurance Industry Tax	13
	7.	Commercial Paper and Long-Term Debt	14
	8.	Shareholders’ Equity	16
	9.	Share-Based Compensation	16
	10.	Commitments and Contingencies	17
	11.	Segment Financial Information	19
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		29
Item 4.	Controls and Procedures		29
Part II. Other Information
Item 1.	Legal Proceedings		30
Item 1A.	Risk Factors		30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		30
Item 6.	Exhibits		31
Signatures			32

PART I

ITEM 1.    FINANCIAL STATEMENTS

UnitedHealth Group

Condensed Consolidated Balance Sheets

(Unaudited)

(in millions, except per share data)	June 30, 2015			December 31, 2014
Assets
Current assets:
Cash and cash equivalents	$	7,887		$	7,495
Short-term investments	1,915			1,741
Accounts receivable, net	6,034			4,252
Other current receivables, net	6,160			5,498
Assets under management	2,863			2,962
Deferred income taxes	514			556
Prepaid expenses and other current assets	2,193			1,052
Total current assets	27,566			23,556
Long-term investments	18,996			18,827
Property, equipment and capitalized software, net	4,473			4,418
Goodwill	34,154			32,940
Other intangible assets, net	3,316			3,669
Other assets	2,918			2,972
Total assets	$	91,423		$	86,382
Liabilities and shareholders’ equity
Current liabilities:
Medical costs payable	$	13,867		$	12,040
Accounts payable and accrued liabilities	10,901			9,247
Other policy liabilities	6,772			5,965
Commercial paper and current maturities of long-term debt	2,693			1,399
Unearned revenues	1,508			1,972
Total current liabilities	35,741			30,623
Long-term debt, less current maturities	15,378			16,007
Future policy benefits	2,491			2,488
Deferred income taxes	1,877			2,065
Other liabilities	1,301			1,357
Total liabilities	56,788			52,540
Commitments and contingencies (Note 10)
Redeemable noncontrolling interests	1,615			1,388
Shareholders’ equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	—			—
Common stock, $0.01 par value - 3,000 shares authorized; 952 and 954 issued and outstanding	10			10
Additional paid in capital	55			—
Retained earnings	35,262			33,836
Accumulated other comprehensive loss	(2,307		)	(1,392		)
Total shareholders’ equity	33,020			32,454
Total liabilities and shareholders’ equity	$	91,423		$	86,382

See Notes to the Condensed Consolidated Financial Statements

1

UnitedHealth Group

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
(in millions, except per share data)	2015			2014			2015			2014
Revenues:
Premiums	$	31,961		$	28,840		$	63,635		$	56,955
Services	2,865			2,447			5,571			4,851
Products	1,223			1,037			2,453			2,035
Investment and other income	214			250			360			441
Total revenues	36,263			32,574			72,019			64,282
Operating costs:
Medical costs	26,026			23,523			51,715			46,731
Operating costs	5,852			5,206			11,801			10,400
Cost of products sold	1,111			929			2,211			1,821
Depreciation and amortization	379			364			757			724
Total operating costs	33,368			30,022			66,484			59,676
Earnings from operations	2,895			2,552			5,535			4,606
Interest expense	(151		)	(155		)	(301		)	(315		)
Earnings before income taxes	2,744			2,397			5,234			4,291
Provision for income taxes	(1,159		)	(989		)	(2,236		)	(1,784		)
Net earnings	$	1,585		$	1,408		$	2,998		$	2,507
Earnings per common share:
Basic	$	1.66		$	1.44		$	3.15		$	2.56
Diluted	$	1.64		$	1.42		$	3.10		$	2.52
Basic weighted-average number of common shares outstanding	952			979			953			981
Dilutive effect of common share equivalents	14			12			14			13
Diluted weighted-average number of common shares outstanding	966			991			967			994
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	8			8			8			9
Cash dividends declared per common share	$	0.5000		$	0.3750		$	0.8750		$	0.6550

See Notes to the Condensed Consolidated Financial Statements

2

UnitedHealth Group

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
(in millions)	2015			2014			2015			2014
Net earnings	$	1,585		$	1,408		$	2,998		$	2,507
Other comprehensive (loss) income:
Gross unrealized (losses) gains on investment securities during the period	(222		)	314			(117		)	480
Income tax effect	80			(114		)	43			(175		)
Total unrealized (losses) gains, net of tax	(142		)	200			(74		)	305
Gross reclassification adjustment for net realized gains included in net earnings	(68		)	(107		)	(71		)	(153		)
Income tax effect	25			39			26			56
Total reclassification adjustment, net of tax	(43		)	(68		)	(45		)	(97		)
Total foreign currency translation gains (losses)	163			151			(796		)	410
Other comprehensive (loss) income	(22		)	283			(915		)	618
Comprehensive income	$	1,563		$	1,691		$	2,083		$	3,125

See Notes to the Condensed Consolidated Financial Statements

3

UnitedHealth Group

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(Unaudited)

	Common Stock				Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive (Loss) Income						Total Shareholders’ Equity
(in millions)	Shares		Amount								Net Unrealized Gains (Losses) on Investments			Foreign Currency Translation (Losses) Gains
Balance at January 1, 2015	954		$	10	$	—		$	33,836		$	223		$	(1,615	)	$	32,454
Net earnings								2,998									2,998
Other comprehensive loss											(119		)	(796		)	(915		)
Issuances of common shares, and related tax effects	7		—		23												23
Share-based compensation, and related tax benefits					319												319
Noncontrolling interests fair value and other adjustments					(73		)										(73		)
Common share repurchases	(9	)	—		(214		)	(739		)							(953		)
Cash dividends paid on common shares								(833		)							(833		)
Balance at June 30, 2015	952		$	10	$	55		$	35,262		$	104		$	(2,411	)	$	33,020
Balance at January 1, 2014	988		$	10	$	—		$	33,047		$	54		$	(962	)	$	32,149
Net earnings								2,507									2,507
Other comprehensive income											208			410			618
Issuances of common shares, and related tax effects	10		—		23												23
Share-based compensation, and related tax benefits					217												217
Common share repurchases	(25	)	—		(240		)	(1,697		)							(1,937		)
Cash dividends paid on common shares								(642		)							(642		)
Balance at June 30, 2014	973		$	10	$	—		$	33,215		$	262		$	(552	)	$	32,935

See Notes to the Condensed Consolidated Financial Statements

4

UnitedHealth Group

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Six Months Ended June 30,
(in millions)	2015			2014
Operating activities
Net earnings	$	2,998		$	2,507
Noncash items:
Depreciation and amortization	757			724
Deferred income taxes	(30		)	(16		)
Share-based compensation	211			188
Other, net	(160		)	(148		)
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable	(1,725		)	(2,131		)
Other assets	(2,178		)	(1,135		)
Medical costs payable	1,988			560
Accounts payable and other liabilities	1,809			2,219
Other policy liabilities	208			(218		)
Unearned revenues	(446		)	(128		)
Cash flows from operating activities	3,432			2,422
Investing activities
Purchases of investments	(4,286		)	(5,477		)
Sales of investments	2,260			4,393
Maturities of investments	1,622			1,544
Cash paid for acquisitions, net of cash assumed	(1,778		)	(523		)
Purchases of property, equipment and capitalized software	(716		)	(716		)
Other, net	48			(99		)
Cash flows used for investing activities	(2,850		)	(878		)
Financing activities
Common stock repurchases	(953		)	(1,937		)
Cash dividends paid	(833		)	(642		)
Proceeds from common stock issuances	242			267
Repayments of long-term debt	(416		)	(172		)
Proceeds from (repayments of) commercial paper, net	1,086			(101		)
Customer funds administered	941			333
Other, net	(188		)	(170		)
Cash flows used for financing activities	(121		)	(2,422		)
Effect of exchange rate changes on cash and cash equivalents	(69		)	14
Increase (decrease) in cash and cash equivalents	392			(864		)
Cash and cash equivalents, beginning of period	7,495			7,276
Cash and cash equivalents, end of period	$	7,887		$	6,412

See Notes to the Condensed Consolidated Financial Statements

5

UnitedHealth Group

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation

UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health and well-being company dedicated to helping people live healthier lives and making the health system work better for everyone. Through its diversified family of businesses, the Company leverages core competencies in advanced, enabling technology; health care data, information and intelligence; and clinical care management and coordination to help meet the demands of the health system. The Company offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.

The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC (2014 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.

Use of Estimates

These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and revenues, valuation and impairment analysis of goodwill and other intangible assets, estimates of other policy liabilities and other current receivables, valuations of certain investments, and estimates and judgments related to income taxes and contingent liabilities. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.

The accounting policies disclosed in Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the 2014 10-K remain unchanged.

Subsequent Events

On July 1, 2015, UnitedHealth Group Incorporated changed its state of incorporation from Minnesota to Delaware pursuant to a plan of conversion. The reincorporation was approved by the Company’s shareholders at its 2015 Annual Meeting of Shareholders held on June 1, 2015. Upon reincorporation, the affairs of UnitedHealth Group Incorporated became subject to the Delaware General Corporation Law, a new certificate of incorporation and new bylaws, and each previously outstanding share of UnitedHealth Group Incorporated’s common stock as a Minnesota corporation (UNH Minnesota) converted into an outstanding share of common stock of UnitedHealth Group Incorporated as a Delaware corporation after the reincorporation (UNH Delaware). The reincorporation was a tax-free reorganization under the U.S. Internal Revenue Code and did not affect the Company’s business operations.

On July 23, 2015, the Company acquired all of the outstanding common shares of Catamaran Corporation (Catamaran) for $12.9 billion in cash and funded Catamaran’s payoff of its outstanding debt and credit facility in connection with the closing. The Company drew its $1.5 billion delayed draw term loan and issued commercial paper and senior unsecured notes to fund the Company’s purchase of Catamaran; see Note 7 of Notes to the Condensed Consolidated Financial Statements for detail on the related July 2015 debt issuance. Catamaran offers retail pharmacy network management, mail service pharmacy, pharmacy claims management and patient-centric specialty pharmacy services to a broad client portfolio, including health plans and employers serving 35 million people, and provides health care information technology solutions to the pharmacy benefits management industry. This acquisition diversifies OptumRx’s customer and business mix, while accelerating its technology leadership and flexible service offerings. As the Catamaran acquisition occurred in the third quarter of 2015, it is not yet practicable to provide disclosures related to the purchase price allocation or pro forma information.

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09). ASU 2014-09 will supersede existing revenue

6

recognition standards with a single model unless those contracts are within the scope of other standards (e.g., an insurance entity’s insurance contracts). The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies can adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. In July 2015, the FASB approved the deferral of ASU 2014-09 for one year and it is effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption at the original effective date, interim and annual periods beginning after December 15, 2016, will be permitted. The Company is currently evaluating the effect of the new revenue recognition guidance.

The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements.

2.Investments

A summary of short-term and long-term investments by major security type is as follows:

(in millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2015
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,859	$	6	$	(4	)	$	1,861
State and municipal obligations	6,196		127		(17		)	6,306
Corporate obligations	7,654		76		(31		)	7,699
U.S. agency mortgage-backed securities	2,091		25		(14		)	2,102
Non-U.S. agency mortgage-backed securities	837		8		(5		)	840
Total debt securities - available-for-sale	18,637		242		(71		)	18,808
Equity securities - available-for-sale	1,559		36		(38		)	1,557
Debt securities - held-to-maturity:
U.S. government and agency obligations	182		3		—			185
State and municipal obligations	15		—		—			15
Corporate obligations	349		—		—			349
Total debt securities - held-to-maturity	546		3		—			549
Total investments	$	20,742	$	281	$	(109	)	$	20,914
December 31, 2014
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,614	$	7	$	(1	)	$	1,620
State and municipal obligations	6,456		217		(5		)	6,668
Corporate obligations	7,241		112		(26		)	7,327
U.S. agency mortgage-backed securities	2,022		39		(5		)	2,056
Non-U.S. agency mortgage-backed securities	872		12		(4		)	880
Total debt securities - available-for-sale	18,205		387		(41		)	18,551
Equity securities - available-for-sale	1,511		36		(25		)	1,522
Debt securities - held-to-maturity:
U.S. government and agency obligations	178		2		—			180
State and municipal obligations	19		—		—			19
Corporate obligations	298		—		—			298
Total debt securities - held-to-maturity	495		2		—			497
Total investments	$	20,211	$	425	$	(66	)	$	20,570

7

The amortized cost and fair value of available-for-sale debt securities as of June 30, 2015, by contractual maturity, were as follows:

(in millions)	Amortized Cost		Fair Value
Due in one year or less	$	2,010	$	2,014
Due after one year through five years	6,943		7,009
Due after five years through ten years	5,016		5,067
Due after ten years	1,740		1,776
U.S. agency mortgage-backed securities	2,091		2,102
Non-U.S. agency mortgage-backed securities	837		840
Total debt securities - available-for-sale	$	18,637	$	18,808

The amortized cost and fair value of held-to-maturity debt securities as of June 30, 2015, by contractual maturity, were as follows:

(in millions)	Amortized Cost		Fair Value
Due in one year or less	$	126	$	126
Due after one year through five years	204		205
Due after five years through ten years	106		107
Due after ten years	110		111
Total debt securities - held-to-maturity	$	546	$	549

The fair value of available-for-sale investments with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:

	Less Than 12 Months					12 Months or Greater					Total
(in millions)	Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses
June 30, 2015
Debt securities - available-for-sale:
U.S. government and agency obligations	$	529	$	(4	)	$	—	$	—		$	529	$	(4	)
State and municipal obligations	1,561		(16		)	22		(1		)	1,583		(17		)
Corporate obligations	3,126		(27		)	229		(4		)	3,355		(31		)
U.S. agency mortgage-backed securities	752		(10		)	126		(4		)	878		(14		)
Non-U.S. agency mortgage-backed securities	364		(4		)	77		(1		)	441		(5		)
Total debt securities - available-for-sale	$	6,332	$	(61	)	$	454	$	(10	)	$	6,786	$	(71	)
Equity securities - available-for-sale	$	148	$	(9	)	$	82	$	(29	)	$	230	$	(38	)
December 31, 2014
Debt securities - available-for-sale:
U.S. government and agency obligations	$	420	$	(1	)	$	—	$	—		$	420	$	(1	)
State and municipal obligations	711		(4		)	99		(1		)	810		(5		)
Corporate obligations	2,595		(17		)	464		(9		)	3,059		(26		)
U.S. agency mortgage-backed securities	—		—			272		(5		)	272		(5		)
Non-U.S. agency mortgage-backed securities	254		(2		)	114		(2		)	368		(4		)
Total debt securities - available-for-sale	$	3,980	$	(24	)	$	949	$	(17	)	$	4,929	$	(41	)
Equity securities - available-for-sale	$	107	$	(6	)	$	88	$	(19	)	$	195	$	(25	)

The Company’s unrealized losses from all securities as of June 30, 2015 were generated from approximately 7,100 positions out of a total of 23,000 positions. The Company believes that it will collect the principal and interest due on its debt securities

8

that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor other factors leading to an other-than-temporary impairment (OTTI). As of June 30, 2015, the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.

The Company’s investments in equity securities consist of investments in Brazilian real denominated fixed-income funds, employee savings plan related investments, venture capital funds, and dividend paying stocks. The Company evaluated its investments in equity securities for severity and duration of unrealized loss, overall market volatility and other market factors.

Net realized gains reclassified out of accumulated other comprehensive income were from the following sources:

	Three Months Ended June 30,						Six Months Ended June 30,
(in millions)	2015			2014			2015			2014
Total OTTI	$	(3	)	$	(4	)	$	(4	)	$	(7	)
Portion of loss recognized in other comprehensive income	—			—			—			—
Net OTTI recognized in earnings	(3		)	(4		)	(4		)	(7		)
Gross realized losses from sales	(5		)	(29		)	(11		)	(39		)
Gross realized gains from sales	76			140			86			199
Net realized gains (included in investment and other income on the Condensed Consolidated Statements of Operations)	68			107			71			153
Income tax effect (included in provision for income taxes on the Condensed Consolidated Statements of Operations)	(25		)	(39		)	(26		)	(56		)
Realized gains, net of taxes	$	43		$	68		$	45		$	97

3. Fair Value

Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.

For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the 2014 10-K.

9

The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets excluding assets and liabilities, related to a Supplemental Health Insurance Program (AARP Program), which are presented in a separate table below:

(in millions)	Quoted Prices in Active Markets (Level 1)			Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)			Total Fair and Carrying Value
June 30, 2015
Cash and cash equivalents	$	7,754		$	133		$	—		$	7,887
Debt securities - available-for-sale:
U.S. government and agency obligations	1,650			211			—			1,861
State and municipal obligations	—			6,306			—			6,306
Corporate obligations	12			7,609			78			7,699
U.S. agency mortgage-backed securities	—			2,102			—			2,102
Non-U.S. agency mortgage-backed securities	—			834			6			840
Total debt securities - available-for-sale	1,662			17,062			84			18,808
Equity securities - available-for-sale	1,226			12			319			1,557
Interest rate swap assets	—			54			—			54
Total assets at fair value	$	10,642		$	17,261		$	403		$	28,306
Percentage of total assets at fair value	38		%	61		%	1		%	100		%
Interest rate swap liabilities	$	—		$	33		$	—		$	33
December 31, 2014
Cash and cash equivalents	$	7,472		$	23		$	—		$	7,495
Debt securities - available-for-sale:
U.S. government and agency obligations	1,427			193			—			1,620
State and municipal obligations	—			6,668			—			6,668
Corporate obligations	2			7,257			68			7,327
U.S. agency mortgage-backed securities	—			2,056			—			2,056
Non-U.S. agency mortgage-backed securities	—			874			6			880
Total debt securities - available-for-sale	1,429			17,048			74			18,551
Equity securities - available-for-sale	1,200			12			310			1,522
Interest rate swap assets	—			62			—			62
Total assets at fair value	$	10,101		$	17,145		$	384		$	27,630
Percentage of total assets at fair value	37		%	62		%	1		%	100		%
Interest rate swap liabilities	$	—		$	55		$	—		$	55

Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs; there were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the six months ended June 30, 2015 or 2014.

10

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:

(in millions)	Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)		Total Fair Value		Total Carrying Value
June 30, 2015
Debt securities - held-to-maturity:
U.S. government and agency obligations	$	185	$	—	$	—	$	185	$	182
State and municipal obligations	—		—		15		15		15
Corporate obligations	92		10		247		349		349
Total debt securities - held-to-maturity	$	277	$	10	$	262	$	549	$	546
Other assets	$	—	$	473	$	—	$	473	$	472
Long-term debt and other financing obligations	$	—	$	17,755	$	—	$	17,755	$	16,664
December 31, 2014
Debt securities - held-to-maturity:
U.S. government and agency obligations	$	180	$	—	$	—	$	180	$	178
State and municipal obligations	—		—		19		19		19
Corporate obligations	46		10		242		298		298
Total debt securities - held-to-maturity	$	226	$	10	$	261	$	497	$	495
Other assets	$	—	$	478	$	—	$	478	$	484
Long-term debt and other financing obligations	$	—	$	18,863	$	—	$	18,863	$	17,085

Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the six months ended June 30, 2015 or 2014.

The carrying amounts reported on the Condensed Consolidated Balance Sheets for other current financial assets and liabilities approximate fair value because of their short-term nature. These assets and liabilities are not listed in the table above.

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level 3 inputs is as follows:

	Three Months Ended									Six Months Ended
(in millions)	Debt Securities			Equity Securities			Total			Debt Securities			Equity Securities			Total
June 30, 2015
Balance at beginning of period	$	79		$	309		$	388		$	74		$	310		$	384
Purchases	6			10			16			10			14			24
Sales	(2		)	(13		)	(15		)	(2		)	(14		)	(16		)
Net unrealized gains (losses) in accumulated other comprehensive income	1			—			1			2			(5		)	(3		)
Net realized gains in investment and other income	—			13			13			—			14			14
Balance at end of period	$	84		$	319		$	403		$	84		$	319		$	403
June 30, 2014
Balance at beginning of period	$	46		$	313		$	359		$	42		$	269		$	311
Purchases	10			6			16			13			50			63
Sales	—			(147		)	(147		)	—			(151		)	(151		)
Net unrealized gains in accumulated other comprehensive income	1			6			7			2			10			12
Net realized gains in investment and other income	—			124			124			—			124			124
Balance at end of period	$	57		$	302		$	359		$	57		$	302		$	359

11

The following table presents quantitative information regarding unobservable inputs that were significant to the valuation of assets measured at fair value on a recurring basis using Level 3 inputs:

					Range
(in millions)	Fair Value		Valuation Technique	Unobservable Input	Low	High
June 30, 2015
Equity securities - available-for-sale
Venture capital portfolios	$	268	Market approach - comparable companies	Revenue multiple	1.0	5.0
				EBITDAmultiple	8.0	10.0
	51		Market approach - recent transactions	Inactive market transactions	N/A	N/A
Total equity securities      available-for-sale	$	319

Also included in the Company’s assets measured at fair value on a recurring basis using Level 3 inputs were $84 million of available-for-sale debt securities as of June 30, 2015, which were not significant.

The Company elected to measure the entirety of the AARP Program assets under management at fair value pursuant to the fair value option. See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on the AARP Program. The following table presents fair value information about the AARP Program-related financial assets and liabilities:

(in millions)	Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Total Fair and Carrying Value
June 30, 2015
Cash and cash equivalents	$	205	$	—	$	205
Debt securities:
U.S. government and agency obligations	431		164		595
State and municipal obligations	—		96		96
Corporate obligations	—		1,287		1,287
U.S. agency mortgage-backed securities	—		400		400
Non-U.S. agency mortgage-backed securities	—		195		195
Total debt securities	431		2,142		2,573
Other investments	—		85		85
Total assets at fair value	$	636	$	2,227	$	2,863
Other liabilities	$	4	$	6	$	10
December 31, 2014
Cash and cash equivalents	$	415	$	—	$	415
Debt securities:
U.S. government and agency obligations	409		245		654
State and municipal obligations	—		95		95
Corporate obligations	—		1,200		1,200
U.S. agency mortgage-backed securities	—		340		340
Non-U.S. agency mortgage-backed securities	—		177		177
Total debt securities	409		2,057		2,466
Other investments	—		81		81
Total assets at fair value	$	824	$	2,138	$	2,962
Other liabilities	$	5	$	13	$	18

12

4. Medicare Part D Pharmacy Benefits

The Condensed Consolidated Balance Sheets include the following amounts associated with the Medicare Part D program:

	June 30, 2015						December 31, 2014
(in millions)	Subsidies		Drug Discount		Risk-Share		Subsidies		Drug Discount		Risk-Share
Other current receivables	$	1,776	$	266	$	20	$	1,801	$	719	$	20
Other policy liabilities	—		164		—		—		302		—

See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on Medicare Part D.

5. Medical Costs Reserve Development

The following table provides details of the Company's medical cost reserve development:

	Three Months Ended June 30,					Six Months Ended June 30,
(in millions)	2015			2014		2015		2014
Related to Prior Years	$	(10	)	$	40	$	130	$	260
Related to Current Year	100			90		N/A		N/A

In the three and six months ended June 30, 2015 and 2014, the medical cost reserve development was driven by a number of individual factors that were not material.

6. Health Insurance Industry Tax

The Patient Protection and Affordable Care Act and a reconciliation measure, the Health Care and Education Reconciliation Act of 2010 (together, Health Reform Legislation) includes an annual, nondeductible insurance industry tax (Health Insurance Industry Tax). As of June 30, 2015, the liability recorded in accounts payable and accrued liabilities related to the Health Insurance Industry Tax was $1.8 billion. The corresponding deferred cost recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets was $900 million. There was no liability or asset related to the Health Insurance Industry Tax recorded as of December 31, 2014 as the Health Insurance Industry Tax was paid in September 2014 and the asset was fully expensed by year end. See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on the Health Insurance Industry Tax.

13

7.     Commercial Paper and Long-Term Debt

Commercial paper and senior unsecured long-term debt consisted of the following:

	June 30, 2015						December 31, 2014
(in millions, except percentages)	Par Value		Carrying Value		Fair Value		Par Value		Carrying Value		Fair Value
Commercial paper	$	1,407	$	1,407	$	1,407	$	321	$	321	$	321
4.875% notes due March 2015 (a)	—		—		—		416		419		419
0.850% notes due October 2015 (a)	625		625		625		625		625		627
5.375% notes due March 2016 (a)	601		614		620		601		623		634
1.875% notes due November 2016 (a)	400		399		405		400		397		406
5.360% notes due November 2016	95		95		101		95		95		103
6.000% notes due June 2017 (a)	441		463		480		441		466		489
1.400% notes due October 2017 (a)	625		621		626		625		616		624
6.000% notes due November 2017 (a)	156		163		174		156		164		175
1.400% notes due December 2017 (a)	750		750		749		750		745		749
6.000% notes due February 2018 (a)	1,100		1,111		1,223		1,100		1,106		1,238
1.625% notes due March 2019 (a)	500		499		494		500		496		493
2.300% notes due December 2019 (a)	500		499		501		500		496		502
3.875% notes due October 2020 (a)	450		451		481		450		450		477
4.700% notes due February 2021 (a)	400		413		441		400		413		450
3.375% notes due November 2021 (a)	500		495		514		500		496		519
2.875% notes due December 2021 (a)	750		747		750		750		748		759
2.875% notes due March 2022 (a)	1,100		1,043		1,068		1,100		1,042		1,104
0.000% notes due November 2022	15		10		11		15		10		11
2.750% notes due February 2023 (a)	625		602		598		625		604		613
2.875% notes due March 2023 (a)	750		771		722		750		777		745
5.800% notes due March 2036	850		845		988		850		845		1,052
6.500% notes due June 2037	500		495		631		500		495		670
6.625% notes due November 2037	650		646		833		650		646		888
6.875% notes due February 2038	1,100		1,085		1,447		1,100		1,085		1,544
5.700% notes due October 2040	300		298		351		300		298		378
5.950% notes due February 2041	350		348		417		350		348		455
4.625% notes due November 2041	600		593		599		600		593		646
4.375% notes due March 2042	502		486		487		502		486		536
3.950% notes due October 2042	625		612		565		625		611		621
4.250% notes due March 2043	750		740		709		750		740		786
Total commercial paper and long-term debt	$	18,017	$	17,926	$	19,017	$	17,347	$	17,256	$	19,034

(a) Fixed-rate debt instruments hedged with interest rate swap contracts. See below for more information on the Company’s interest rate swaps.

The Company’s long-term debt obligations also included $145 million and $150 million of other financing obligations, of which $47 million and $34 million were current as of June 30, 2015 and December 31, 2014, respectively.

Commercial Paper and Bank Credit Facilities

Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of June 30, 2015, the Company’s outstanding commercial paper had a weighted-average annual interest rate of 0.3%.

The Company has $3.0 billion five-year and $1.0 billion 364-day revolving bank credit facilities with 23 banks, which mature in November 2019 and November 2015, respectively. The Company also has a $2.0 billion 364-day revolving bank credit facility with 22 banks maturing in April 2016. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. In addition, the Company has a $1.5 billion delayed draw term loan to fund the Catamaran acquisition. As of June 30, 2015, no amounts had been drawn on any of the bank credit facilities or the term loan. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities and the term loan as of June 30, 2015, annual interest rates would have ranged from 1.0% to 1.3%.

14

July 2015 Debt Issuance

In July 2015, the Company issued commercial paper and senior unsecured notes and drew on its delayed draw term loan. The proceeds of these debt issuances were used to fund the Catamaran acquisition. For more detail on the Catamaran acquisition see Note 1 of the Notes to the Condensed Consolidated Financial Statements.

(in millions, except percentages)	Par Value
Floating rate notes due January 2017	$	750
1.450% notes due July 2017	750
1.900% notes due July 2018	1,500
2.700% notes due July 2020	1,500
3.350% notes due July 2022	1,000
3.750% notes due July 2025	2,000
4.625% notes due July 2035	1,000
4.750% notes due July 2045	2,000
Total July 2015 Issuance	$	10,500
Delayed draw term loan	$	1,500
Commercial paper	$	2,400

Debt Covenants

The Company’s bank credit facilities contain various covenants including requiring the Company to maintain a debt to debt-plus-equity ratio of not more than 50%. The Company was in compliance with its debt covenants as of June 30, 2015.

Interest Rate Swap Contracts

The Company uses interest rate swap contracts to convert a portion of its interest rate exposure from fixed rates to floating rates to more closely align interest expense with interest income received on its variable rate financial assets. The floating rates are benchmarked to LIBOR. The swaps are designated as fair value hedges on the Company’s fixed-rate debt. Since the critical terms of the swaps match those of the debt being hedged, they are considered to be highly effective hedges and all changes in the fair values of the swaps are recorded as adjustments to the carrying value of the related debt with no net impact recorded on the Condensed Consolidated Statements of Operations. Both the hedge fair value changes and the offsetting debt adjustments are recorded in interest expense on the Condensed Consolidated Statements of Operations. The following table summarizes the location and fair value of the interest rate swap fair value hedges on the Company’s Condensed Consolidated Balance Sheet:

Type of Fair Value Hedge	Notional Amount		Fair Value		Balance Sheet Location
	(in billions)		(in millions)
June 30, 2015
Interest rate swap contracts	$	10.3	54		Other assets
			33		Other liabilities
December 31, 2014
Interest rate swap contracts	$	10.7	$	62	Other assets
			55		Other liabilities

The following table provides a summary of the effect of changes in fair value of fair value hedges on the Company’s Condensed Consolidated Statements of Operations:

	Three Months Ended June 30,						Six Months Ended  June 30,
(in millions)	2015			2014			2015			2014
Hedge - interest rate swap (loss) gain recognized in interest expense	$	(208	)	$	67		$	14		$	133
Hedged item - long-term debt gain (loss) recognized in interest expense	208			(67		)	(14		)	(133		)
Net impact on the Company’s Condensed Consolidated Statements of Operations	$	—		$	—		$	—		$	—

15

8. Shareholders' Equity

Share Repurchase Program

Under its Board of Directors’ authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company’s capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time in open market purchases or other types of transactions (including prepaid or structured repurchase programs), subject to certain Board restrictions. During the six months ended June 30, 2015, the Company repurchased 9 million shares at an average price of $111.56 per share and an aggregate cost of $953 million. As of June 30, 2015, the Company had Board authorization to purchase up to 63 million shares of its common stock.

Dividends

In June 2015, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to equal an annual dividend rate of $2.00 per share compared to the annual dividend rate of $1.50 per share, which the Company had paid since June 2014. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

The following table provides details of the Company’s 2015 dividend payments:

Payment Date	Amount per Share		Total Amount Paid
			(in millions)
March 24, 2015	$	0.3750	$	357
June 24, 2015	0.5000		476

9. Share-Based Compensation

In June 2015, the Company’s shareholders approved an amendment to the 2011 Stock Incentive Plan (Plan). The approved amendment increased the number of shares authorized for issuance under the Plan by 70 million and removed the limit in the Plan for shares other than options and stock-settled stock appreciation rights (SARs) that can be awarded. The Company’s outstanding share-based awards consist mainly of nonqualified stock options, SARs and restricted stock and restricted stock units (collectively, restricted shares). As of June 30, 2015, the Company had 85 million shares available for future grants of share-based awards under its share-based compensation plan.

Stock Options and SARs

Stock option and SAR activity for the six months ended June 30, 2015 is summarized in the table below:

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life	Aggregate Intrinsic Value
	(in millions)				(in years)	(in millions)
Outstanding at beginning of period	33		$	53
Granted	8		109
Exercised	(6	)	52
Outstanding at end of period	35		66		6.2	$	1,971
Exercisable at end of period	18		47		3.7	1,335
Vested and expected to vest, end of period	34		66		6.1	1,933

Restricted Shares

Restricted share activity for the six months ended June 30, 2015 is summarized in the table below:

(shares in millions)	Shares		Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period	9		$	61
Granted	2		109
Vested	(4	)	57
Nonvested at end of period	7		79

16

Other Share-Based Compensation Data

(in millions, except per share amounts)	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Stock Options and SARs
Weighted-average grant date fair value of shares granted, per share	$	21	$	19	$	23	$	22
Total intrinsic value of stock options and SARs exercised	107		74		328		286
Restricted Shares
Weighted-average grant date fair value of shares granted, per share	118		80		109		70
Total fair value of restricted shares vested	12		9		407		423
Share-Based Compensation Items
Share-based compensation expense, before tax	86		83		211		188
Share-based compensation expense, net of tax effects	76		71		177		157
Income tax benefit realized from share-based award exercises	36		24		174		143

(in millions, except years)	June 30, 2015
Unrecognized compensation expense related to share awards	$	551
Weighted-average years to recognize compensation expense	1.4

Share-Based Compensation Recognition and Estimates

The principal assumptions the Company used in calculating grant-date fair value for stock options and SARs were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2015	2014	2015	2014
Risk-free interest rate	1.7%	1.8%	1.6% - 1.7%	1.7% - 1.8%
Expected volatility	22.5%	31.7%	22.5% - 24.1%	31.7% - 39.6%
Expected dividend yield	1.7%	1.9%	1.4% - 1.7%	1.6% - 1.9%
Forfeiture rate	5.0%	5.0%	5.0%	5.0%
Expected life in years	5.6	5.4	5.6 - 6.1	5.4

10. Commitments and Contingencies

Legal Matters

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims, and claims related to health care benefits coverage and other business practices.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.

Litigation Matters

California Claims Processing Matter.On January 25, 2008, the California Department of Insurance (CDI) issued an Order to Show Cause to PacifiCare Life and Health Insurance Company, a subsidiary of the Company, alleging violations of certain insurance statutes and regulations related to an alleged failure to include certain language in standard claims correspondence, timeliness and accuracy of claims processing, interest payments, care provider contract implementation, care provider dispute resolution and other related matters. Although the Company believes that CDI had never before issued a fine in excess of $8

17

million, CDI advocated a fine of approximately $325 million in this matter. The matter was the subject of an administrative hearing before a California administrative law judge beginning in December 2009, and in August 2013, the administrative law judge issued a nonbinding proposed decision recommending a fine of $11.5 million. The California Insurance Commissioner rejected the administrative law judge’s recommendation and on June 9, 2014, issued his own decision imposing a fine of approximately $174 million. On July 10, 2014, the Company filed a lawsuit in California state court challenging the Commissioner’s decision. The Company cannot reasonably estimate the range of loss, if any, that may result from this matter given the procedural status of the dispute, the wide range of possible outcomes, the legal issues presented (including the legal basis for the majority of the alleged violations), the inherent difficulty in predicting a regulatory fine in the event of a remand, and the various remedies and levels of judicial review that remain available to the Company.

Government Investigations, Audits and Reviews

The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, the Brazilian national regulatory agency for private health insurance and plans (the Agência Nacional de Saúde Suplementar), state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the Brazilian federal revenue service (the Secretaria da Receita Federal), the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other things, compliance with coding and other requirements under the Medicare risk-adjustment model.

In February 2012, CMS announced a final Risk Adjustment Data Validation (RADV) audit and payment adjustment methodology and that it will conduct RADV audits beginning with the 2011 payment year. These audits involve a review of medical records maintained by care providers and may result in retrospective adjustments to payments made to health plans. CMS has not communicated how the final payment adjustment under its methodology will be implemented.

The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.

Guaranty Fund Assessments

Under state guaranty fund laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies. In 2009, the Pennsylvania Insurance Commissioner placed long term care insurer Penn Treaty Network America Insurance Company and its subsidiary (Penn Treaty), neither of which is affiliated with the Company, in rehabilitation and petitioned a state court for approval to liquidate Penn Treaty. In 2012, the court denied the liquidation petition and ordered the Insurance Commissioner to submit a rehabilitation plan. The court held a hearing on July 13, 2015 to begin its consideration of the latest proposed rehabilitation plan.

If the current proposed rehabilitation plan, which contemplates the partial liquidation of Penn Treaty, is approved by the court, the Company’s insurance entities and other insurers may be required to pay a portion of Penn Treaty’s policyholder claims through state guaranty association assessments in future periods. The Company intends to vigorously challenge the proposed rehabilitation plan. The Company is currently unable to estimate losses or ranges of losses because the Company cannot predict whether, when or to what extent Penn Treaty will ultimately be declared insolvent, the amount of the insolvency, if any, the amount and timing of any associated guaranty fund assessments or the availability and amount of any premium tax and other potential offsets.

18

11. Segment Financial Information

The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more information on the Company’s segments see Part I, Item I, “Business” and Note 13 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company's 2014 10-K.

The following table presents the reportable segment financial information:

			Optum
(in millions)	UnitedHealthcare		OptumHealth		OptumInsight		OptumRx		Optum Eliminations			Optum		Corporate and Eliminations			Consolidated
Three Months Ended June 30, 2015
Revenues - external customers:
Premiums	$	31,186	$	775	$	—	$	—	$	—		$	775	$	—		$	31,961
Services	1,715		579		542		29		—			1,150		—			2,865
Products	1		11		16		1,195		—			1,222		—			1,223
Total revenues - external customers	32,902		1,365		558		1,224		—			3,147		—			36,049
Total revenues - intersegment	—		2,031		851		7,688		(172		)	10,398		(10,398		)	—
Investment and other income	171		42		—		1		—			43		—			214
Total revenues	$	33,073	$	3,438	$	1,409	$	8,913	$	(172	)	$	13,588	$	(10,398	)	$	36,263
Earnings from operations	$	2,031	$	253	$	271	$	340	$	—		$	864	$	—		$	2,895
Interest expense	—		—		—		—		—			—		(151		)	(151		)
Earnings before income taxes	$	2,031	$	253	$	271	$	340	$	—		$	864	$	(151	)	$	2,744
Three Months Ended June 30, 2014
Revenues - external customers:
Premiums	$	28,213	$	627	$	—	$	—	$	—		$	627	$	—		$	28,840
Services	1,646		242		532		27		—			801		—			2,447
Products	1		4		14		1,018		—			1,036		—			1,037
Total revenues - external customers	29,860		873		546		1,045		—			2,464		—			32,324
Total revenues - intersegment	—		1,674		697		6,955		(115		)	9,211		(9,211		)	—
Investment and other income	211		39		—		—		—			39		—			250
Total revenues	$	30,071	$	2,586	$	1,243	$	8,000	$	(115	)	$	11,714	$	(9,211	)	$	32,574
Earnings from operations	$	1,824	$	224	$	213	$	291	$	—		$	728	$	—		$	2,552
Interest expense	—		—		—		—		—			—		(155		)	(155		)
Earnings before income taxes	$	1,824	$	224	$	213	$	291	$	—		$	728	$	(155	)	$	2,397

19

			Optum
(in millions)	UnitedHealthcare		OptumHealth		OptumInsight		OptumRx		Optum Eliminations			Optum		Corporate and Eliminations			Consolidated
Six Months Ended June 30, 2015
Revenues - external customers:
Premiums	$	62,091	$	1,544	$	—	$	—	$	—		$	1,544	$	—		$	63,635
Services	3,318		1,100		1,101		52		—			2,253		—			5,571
Products	1		16		36		2,400		—			2,452		—			2,453
Total revenues - external customers	65,410		2,660		1,137		2,452		—			6,249		—			71,659
Total revenues - intersegment	—		3,994		1,662		14,755		(331		)	20,080		(20,080		)	—
Investment and other income	286		73		—		1		—			74		—			360
Total revenues	$	65,696	$	6,727	$	2,799	$	17,208	$	(331	)	$	26,403	$	(20,080	)	$	72,019
Earnings from operations	$	3,929	$	487	$	493	$	626	$	—		$	1,606	$	—		$	5,535
Interest expense	—		—		—		—		—			—		(301		)	(301		)
Earnings before income taxes	$	3,929	$	487	$	493	$	626	$	—		$	1,606	$	(301	)	$	5,234
Six Months Ended June 30, 2014
Revenues - external customers:
Premiums	$	55,724	$	1,231	$	—	$	—	$	—		$	1,231	$	—		$	56,955
Services	3,232		505		1,057		57		—			1,619		—			4,851
Products	2		11		40		1,982		—			2,033		—			2,035
Total revenues - external customers	58,958		1,747		1,097		2,039		—			4,883		—			63,841
Total revenues - intersegment	—		3,345		1,393		13,419		(230		)	17,927		(17,927		)	—
Investment and other income	367		74		—		—		—			74		—			441
Total revenues	$	59,325	$	5,166	$	2,490	$	15,458	$	(230	)	$	22,884	$	(17,927	)	$	64,282
Earnings from operations	$	3,228	$	435	$	410	$	533	$	—		$	1,378	$	—		$	4,606
Interest expense	—		—		—		—		—			—		(315		)	(315		)
Earnings before income taxes	$	3,228	$	435	$	410	$	533	$	—		$	1,378	$	(315	)	$	4,291

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2014 10-K, including the Consolidated Financial Statements and Notes in Part II, Item 8, “Financial Statements” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.

Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2014 10-K and in the discussion below.

EXECUTIVE OVERVIEW

General

UnitedHealth Group is a diversified health and well-being company dedicated to helping people live healthier lives and making the health system work better for everyone. Through our diversified family of businesses, we leverage core competencies in advanced, enabling technology; health care data, information and intelligence; and clinical care management and coordination to help meet the demands of the health system. We offer a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.

Further information on our business is included in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2014 10-K and additional information on our segments can be found in this Item 2 and in Note 11 of Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report.

Business Trends

Our businesses participate in the U.S., Brazilian and certain other international health economies. In the United States, health care spending comprises approximately 18% of gross domestic product and has grown consistently for many years. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macro-economic conditions and regulatory changes, including enacted health reform legislation in the United States, which have impacted and could further impact our results of operations.

Pricing Trends. To price our health care benefit products, we start with our view of expected future costs. We frequently evaluate and adjust our approach in each of the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations. Our review of regulatory considerations involves a focus on minimum loss ratio (MLR) thresholds and the risk adjustment, risk corridor and reinsurance provisions that impact the small group and individual markets. We will continue seeking to balance growth and profitability across all of these dimensions.

We continue to be under pressure from ongoing market competition in commercial products and from government payment rates. The intensity of commercial pricing competition depends on local market conditions and competitive dynamics. Annual commercial premium rate increases are subject to federal and state review and approval procedures. The Medicare Advantage rate structure is changing and funding has been cut in recent years, with additional reductions taking effect in 2015, as discussed below in “Regulatory Trends and Uncertainties.” Although we expect continued Medicaid revenue increases due to anticipated growth in the number of people served through our offerings, the reimbursement rate environment creates the risk of downward pressure on Medicaid net margin percentages.

Medical Cost Trends. Our medical cost trends are primarily related to changes in unit costs, health system utilization and prescription drug costs. Although Health Reform Legislation and prescription drug utilization, particularly use of new specialty medications, have exerted upward pressure on medical cost trends, our medical cost management strategies have had a moderating impact on utilization trends in recent years.

Regulatory Trends and Uncertainties

Following is a summary of management’s view of the trends and uncertainties related to some of the key provisions of Health Reform Legislation and other regulatory items. For additional information regarding Health Reform Legislation and regulatory trends and uncertainties, see Part I, Item 1, “Business - Government Regulation”, Item 1A, “Risk Factors”, and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2014 10-K.

Medicare Advantage Rates. Medicare Advantage rates have been cut over the last several years, with additional funding reductions to be phased-in through 2017. The impact of these cuts to our 2015 Medicare Advantage revenues is partially mitigated by reductions in provider reimbursements for those care providers with rates indexed to Medicare Advantage revenues or Medicare fee-for-service reimbursement rates. These factors affected our plan benefit designs, market participation, growth prospects and earnings expectations for our Medicare Advantage plans this year.

The 2016 Final Rate notice released by CMS in April 2015 provided some progress toward more stable program rates, with the industry seeing an average increase in funding of 125 basis points. However, these rates still trail the pace of the rising cost of medical care and create continued pressure on the Medicare Advantage program. 

Our Medicare Advantage rates are currently enhanced by CMS quality bonuses in certain counties based on our local plans’ star ratings. The level of star ratings from CMS, based upon specified clinical and operational performance standards, will impact future quality bonuses. In addition, star ratings affect the amount of savings a plan has to generate to offer supplemental benefits, which ultimately may affect the plan’s membership and revenue. The previous star bonus program, which paid bonuses to qualifying plans rated 3 stars or higher, expired after 2014. In 2015, quality bonus payments will be paid only to plans rated 4 stars and higher. For the 2015 star bonus payment year, 39% of our Medicare Advantage members are enrolled in plans rated 4 stars or higher. We are dedicating substantial resources to advance our quality scores and star ratings to strengthen our local market programs and further improve our performance in future years.

20

Health Insurance Industry Tax and Premium Stabilization Programs. Health Reform Legislation includes a Health Insurance Industry Tax levied on risk-based products proportionally across the industry. The industry-wide amount of the annual tax is $11.3 billion in 2015 and we expect that our proportionate share will be $1.8 billion. Health Reform Legislation also includes three programs designed to stabilize the health insurance markets. These programs encompass: a temporary reinsurance program; a temporary risk corridors program; and a permanent risk adjustment program. Of the $8 billion allocated for the reinsurance program in 2015, $6 billion will fund the reinsurance pool and $2 billion will fund the U.S. Treasury. While funding for the reinsurance program will come from all commercial lines of business, only market reform compliant individual business will be eligible for reinsurance recoveries.

For further detail on the Health Insurance Industry Tax and Premium Stabilization Programs, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements” in our 2014 10-K.

Exchanges and Coverage Expansion. We and our competitors are adapting product, network and marketing strategies across markets to anticipate new or expanding distribution channels, including public exchanges, private exchanges and off exchange purchasing. In 2015, we are participating in 23 individual public exchanges and in 12 small group public exchanges.

RESULTS SUMMARY

The following table summarizes our consolidated results of operations and other financial information:

(in millions, except percentages and per share data)	Three Months Ended June 30,						Increase/(Decrease)					Six Months Ended June 30,						Increase/(Decrease)
	2015			2014			2015 vs. 2014					2015			2014			2015 vs. 2014
Revenues:
Premiums	$	31,961		$	28,840		$	3,121		11	%	$	63,635		$	56,955		$	6,680		12	%
Services	2,865			2,447			418			17		5,571			4,851			720			15
Products	1,223			1,037			186			18		2,453			2,035			418			21
Investment and other income	214			250			(36		)	(14	)	360			441			(81		)	(18	)
Total revenues	36,263			32,574			3,689			11		72,019			64,282			7,737			12
Operating costs:
Medical costs	26,026			23,523			2,503			11		51,715			46,731			4,984			11
Operating costs	5,852			5,206			646			12		11,801			10,400			1,401			13
Cost of products sold	1,111			929			182			20		2,211			1,821			390			21
Depreciation and amortization	379			364			15			4		757			724			33			5
Total operating costs	33,368			30,022			3,346			11		66,484			59,676			6,808			11
Earnings from operations	2,895			2,552			343			13		5,535			4,606			929			20
Interest expense	(151		)	(155		)	(4		)	(3	)	(301		)	(315		)	(14		)	(4	)
Earnings before income taxes	2,744			2,397			347			14		5,234			4,291			943			22
Provision for income taxes	(1,159		)	(989		)	170			17		(2,236		)	(1,784		)	452			25
Net earnings	$	1,585		$	1,408		$	177		13		$	2,998		$	2,507		$	491		20
Diluted earnings per common share	$	1.64		$	1.42		$	0.22		15	%	$	3.10		$	2.52		$	0.58		23	%
Medical care ratio (a)	81.4		%	81.6		%	(0.2		)%			81.3		%	82.0		%	(0.7		)%
Operating cost ratio	16.1			16.0			0.1					16.4			16.2			0.2
Operating margin	8.0			7.8			0.2					7.7			7.2			0.5
Tax rate	42.2			41.3			0.9					42.7			41.6			1.1
Net earnings margin	4.4			4.3			0.1					4.2			3.9			0.3
Return on equity (b)	19.5		%	17.2		%	2.3		%			18.5		%	15.4		%	3.1		%

(a) Medical care ratio is calculated as medical costs divided by premium revenue.

(b) Return on equity is calculated as annualized net earnings divided by average equity. Average equity is calculated using the equity balance at the end of the preceding year and the equity balances at the end of each of the quarters in the periods presented.

21

SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS

The following summarizes select second quarter 2015 year-over-year operating comparisons to second quarter 2014 and other 2015 significant items.

• Consolidated revenues grew 11%, UnitedHealthcare revenues grew 10% and Optum revenues grew 16%.

• UnitedHealthcare grew to serve an additional 1.6 million people domestically.

• Earnings from operations increased 13%, including an increase of 11% at UnitedHealthcare and 19% at Optum.

• Diluted earnings per common share increased 15% to $1.64.

• Year-to-date 2015 cash flows from operations were $3.4 billion an increase of 42%.

• On July 23, 2015, we acquired Catamaran through the purchase of all of its outstanding common stock for cash. See Note 1 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information about this transaction.

2015 RESULTS OF OPERATIONS COMPARED TO 2014 RESULTS

Consolidated Financial Results

Revenues

The increase in revenues during the three and six months ended June 30, 2015 was primarily driven by growth in the number of individuals served across our benefits businesses and growth across all of Optum’s businesses.

Medical Costs and Medical Care Ratio

Medical costs during the three and six months ended June 30, 2015 increased due to risk-based membership growth in our benefits businesses. The medical care ratio for the three and six months ended June 30, 2015 decreased 20 and 70 basis points, respectively, primarily due to premium increases to cover the 2015 step up in the Health Insurance Industry Tax and our performance in managing health care costs across our benefits businesses.

Operating Cost Ratio

The increase in our operating cost ratio during the three and six months ended June 30, 2015 was due to services business acquisitions, which carry proportionately higher operating costs than premium-based business, largely offset by growth in government benefits programs and productivity gains.

22

Reportable Segments

See Note 11 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1, “Financial Statements” for more information on our segments. The following table presents a summary of the reportable segment financial information:

	Three Months Ended June 30,						Increase/(Decrease)					Six Months Ended June 30,						Increase/(Decrease)
(in millions, except percentages)	2015			2014			2015 vs. 2014					2015			2014			2015 vs. 2014
Revenues
UnitedHealthcare	$	33,073		$	30,071		$	3,002		10	%	$	65,696		$	59,325		$	6,371		11	%
OptumHealth	3,438			2,586			852			33		6,727			5,166			1,561			30
OptumInsight	1,409			1,243			166			13		2,799			2,490			309			12
OptumRx	8,913			8,000			913			11		17,208			15,458			1,750			11
Optum eliminations	(172		)	(115		)	57			50		(331		)	(230		)	101			44
Optum	13,588			11,714			1,874			16		26,403			22,884			3,519			15
Eliminations	(10,398		)	(9,211		)	1,187			13		(20,080		)	(17,927		)	2,153			12
Consolidated revenues	$	36,263		$	32,574		$	3,689		11	%	$	72,019		$	64,282		$	7,737		12	%
Earnings from operations
UnitedHealthcare	$	2,031		$	1,824		$	207		11	%	$	3,929		$	3,228		$	701		22	%
OptumHealth	253			224			29			13		487			435			52			12
OptumInsight	271			213			58			27		493			410			83			20
OptumRx	340			291			49			17		626			533			93			17
Optum	864			728			136			19		1,606			1,378			228			17
Consolidated earnings from operations	$	2,895		$	2,552		$	343		13	%	$	5,535		$	4,606		$	929		20	%
Operating margin
UnitedHealthcare	6.1		%	6.1		%	—		%			6.0		%	5.4		%	0.6		%
OptumHealth	7.4			8.7			(1.3		)			7.2			8.4			(1.2		)
OptumInsight	19.2			17.1			2.1					17.6			16.5			1.1
OptumRx	3.8			3.6			0.2					3.6			3.4			0.2
Optum	6.4			6.2			0.2					6.1			6			0.1
Consolidated operating margin	8.0		%	7.8		%	0.2		%			7.7		%	7.2		%	0.5		%

UnitedHealthcare

The following table summarizes UnitedHealthcare revenues by business:

	Three Months Ended June 30,				Increase/(Decrease)					Six Months Ended June 30,				Increase/(Decrease)
(in millions, except percentages)	2015		2014		2015 vs. 2014					2015		2014		2015 vs. 2014
UnitedHealthcare Employer & Individual	$	11,845	$	10,729	$	1,116		10	%	23,268		$	21,686	$	1,582		7	%
UnitedHealthcare Medicare & Retirement	12,559		11,785		774			7		25,340		23,287		2,053			9
UnitedHealthcare Community & State	7,205		5,764		1,441			25		14,110		10,938		3,172			29
UnitedHealthcare Global	1,464		1,793		(329		)	(18	)	2,978		3,414		(436		)	(13	)
Total UnitedHealthcare revenues	$	33,073	$	30,071	$	3,002		10	%	$	65,696	$	59,325	$	6,371		11	%

23

The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:

	June 30,		Increase/(Decrease)
(in thousands, except percentages)	2015	2014	2015 vs. 2014
Commercial risk-based	8,105	7,610	495		7	%
Commercial fee-based, including TRICARE	21,295	21,240	55		—
Total commercial	29,400	28,850	550		2
Medicare Advantage	3,205	2,985	220		7
Medicaid	5,210	4,670	540		12
Medicare Supplement (Standardized)	3,965	3,665	300		8
Total public and senior	12,380	11,320	1,060		9
Total UnitedHealthcare - domestic medical	41,780	40,170	1,610		4
International	4,080	4,765	(685	)	(14	)
Total UnitedHealthcare - medical	45,860	44,935	925		2	%
Supplemental Data:
Medicare Part D stand-alone	5,075	5,150	(75	)	(1	)%

The increase in commercial risk-based enrollment was a result of strong participation in UnitedHealthcare’s individual public exchange products and favorable annual renewal activity and new business wins in the employer group segment. Medicare Advantage participation increased year-over-year primarily due to growth in people served through employer-sponsored group Medicare Advantage plans. Medicaid growth was driven by the combination of ACA Medicaid expansion, states launching new programs to complement established programs and growth in established programs, which was partially offset by a decrease of 175,000 people in one market, where an additional offering was introduced by the state in the first quarter of 2015. Medicare Supplement growth reflected strong customer retention and new sales. The number of people served internationally decreased year-over-year primarily due to pricing and underwriting disciplines in Brazil in response to regulatory actions.

UnitedHealthcare’s revenue growth during the three and six months ended June 30, 2015 was due to growth in the number of individuals served across its businesses and price increases reflecting underlying medical cost trends.

UnitedHealthcare’s operating earnings for the three and six months ended June 30, 2015 increased year-over-year due to a combination of strong growth across the business along with improved medical cost management and increased productivity. 

Optum

Total revenues increased for the three and six months ended June 30, 2015 as each reporting segment advanced revenues by double-digit percentages as a result of the factors discussed below.

The increases in Optum’s earnings from operations for the three and six months ended June 30, 2015 were driven by revenue growth. For the six months ended June 30, 2015, the increase in earnings from operations was partially offset by transaction costs related to the acquisition of Catamaran at OptumRx.

The results by segment were as follows:

OptumHealth

Revenue and earnings from operations increased at OptumHealth during the three and six months ended June 30, 2015 primarily due to growth in the number of patients served across its OptumCare health delivery businesses as well as the impact of acquisitions. The operating margins for the three and six months ended June 30, 2015 decreased from the prior year primarily due to stronger growth in lower margin lines of business and investments made to support future growth.

OptumInsight

Revenue at OptumInsight for the three and six months ended June 30, 2015 increased primarily due to growth in care provider revenue management services. Earnings from operations and operating margins for the three and six months ended June 30, 2015 increased primarily due to increased revenues, growth in technology services and simplification of lines of business.

OptumRx

OptumRx revenue, earnings from operations and operating margin for the three and six months ended June 30, 2015 increased due to an increase in prescription volume driven by serving an increasing number of people, increases in revenue per script and

24

growth in specialty medications. The increases in earnings from operations and operating margin for the six months ended June 30, 2015 were partially offset by transaction costs related to the acquisition of Catamaran. For more information about the Catamaran transaction, see Note 1 in Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report.

LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES

Liquidity

Introduction

We manage our liquidity and financial position in the context of our overall business strategy. We continually forecast and manage our cash, investments, working capital balances and capital structure to meet the short-term and long-term obligations of our businesses while seeking to maintain liquidity and financial flexibility. Cash flows generated from operating activities are principally from earnings before noncash expenses.

Our regulated subsidiaries generate significant cash flows from operations and are subject to financial regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital, as defined by each jurisdiction, and restrict the timing and amount of dividends and other distributions that may be paid to their parent companies. In the United States, these regulations and standards are generally consistent with model regulations established by the National Association of Insurance Commissioners. These standards generally permit dividends to be paid from statutory unassigned surplus of the regulated subsidiary and are limited based on the regulated subsidiary’s level of statutory net income and statutory capital and surplus. These dividends are referred to as “ordinary dividends” and generally may be paid without prior regulatory approval. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, the entire dividend is generally considered an “extraordinary dividend” and must receive prior regulatory approval.

For the six months ended June 30, 2015, our U.S. regulated subsidiaries paid their parent companies dividends of $2.4 billion, and we had approximately $1.9 billion in ordinary dividend capacity remaining for the year.

Our nonregulated businesses also generate cash flows from operations that are available for general corporate use. Cash flows generated by these entities, combined with dividends from our regulated entities and financing through the issuance of long-term debt as well as issuance of commercial paper or the ability to draw under our committed credit facilities, further strengthen our operating and financial flexibility. We use these cash flows to expand our businesses through acquisitions, reinvest in our businesses through capital expenditures, repay debt, and return capital to our shareholders through shareholder dividends and/or repurchases of our common stock, depending on market conditions.

25

Summary of our Major Sources and Uses of Cash and Cash Equivalents

	Six Months Ended June 30,						Increase/(Decrease)
(in millions)	2015			2014			2015 vs. 2014
Sources of cash:
Cash provided by operating activities	$	3,432		$	2,422		$	1,010
Customer funds administered	941			333			608
Issuances of commercial paper and long-term debt, net of repayments	670			—			670
Proceeds from common stock issuances	242			267			(25		)
Sales and maturities of investments, net of purchases	—			460			(460		)
Other	48			—			48
Total sources of cash	5,333			3,482
Uses of cash:
Common stock repurchases	(953		)	(1,937		)	984
Cash paid for acquisitions, net of cash assumed	(1,778		)	(523		)	(1,255		)
Purchases of investments, net of sales and maturities	(404		)	—			(404		)
Purchases of property, equipment and capitalized software, net	(716		)	(716		)	—
Cash dividends paid	(833		)	(642		)	(191		)
Repayments of long-term debt and commercial paper, net of issuances	—			(273		)	273
Other	(188		)	(269		)	81
Total uses of cash	(4,872		)	(4,360		)
Effect of exchange rate changes on cash and cash equivalents	(69		)	14			(83		)
Net increase (decrease) in cash and cash equivalents	$	392		$	(864	)	$	1,256

2015 Cash Flows Compared to 2014 Cash Flows

Cash flows provided by operating activities in 2015 increased primarily due to improvement in net earnings and growth in risk-based products, which increased medical costs payable, partially offset by the first quarter 2015 payment of reinsurance program fees.

Other significant changes in sources or uses of cash year-over-year included decreased share repurchases in 2015 compared to 2014, net debt issuances in 2015 compared to net repayments in 2014, increased cash paid for acquisitions in 2015 compared to 2014, and a change in investment activity to net purchases in 2015 compared to net sales in 2014.

Financial Condition

As of June 30, 2015, our cash, cash equivalent and available-for-sale investment balances of $28.3 billion included $7.9 billion of cash and cash equivalents (of which $654 million was available for general corporate use), $18.8 billion of debt securities and $1.6 billion of investments in equity securities consisting of investments in non-U.S. dollar fixed-income funds; employee savings plan related investments; venture capital funds; and dividend paying stocks. Given the significant portion of our portfolio held in cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. The use of different market assumptions or valuation methodologies, especially those used in valuing our $403 million of available-for-sale Level 3 securities (those securities priced using significant unobservable inputs), may have an effect on the estimated fair values of our investments. Due to the subjective nature of these assumptions, the estimates may not be indicative of the actual exit price if we had sold the investment at the measurement date. Other sources of liquidity, primarily from operating cash flows and our commercial paper program, which is supported by our bank credit facilities, reduce the need to sell investments during adverse market conditions. See Note 3 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for further detail concerning our fair value measurements.

Our available-for-sale debt portfolio had a weighted-average duration of 3.3 years and a weighted-average credit rating of “AA” as of June 30, 2015. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

26

Capital Resources and Uses of Liquidity

In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:

Commercial Paper and Bank Credit Facilities. Our bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through third-party broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

Our bank credit facilities contain various covenants, including covenants requiring us to maintain a debt to debt-plus-equity ratio of not more than 50%. Our debt to debt-plus-equity ratio, calculated as the sum of debt divided by the sum of debt and shareholders’ equity, which reasonably approximates the actual covenant ratio, was 35.4% as of June 30, 2015.

Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, for example, to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. In July 2015, we issued debt to fund the acquisition of Catamaran. For more information on this debt issuance, see Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

Credit Ratings. Our credit ratings as of June 30, 2015, were as follows:

	Moody’s		Standard & Poor’s		Fitch(a)		A.M. Best
	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook
Senior unsecured debt	A3	Negative	A+	Negative	A-	Negative Watch	bbb+	Stable
Commercial paper	P-2	n/a	A-1	n/a	F1	n/a	AMB-2	n/a

(a) In July 2015, Fitch removed us from Negative Watch, affirmed our ratings, and changed our outlook to Negative.

The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. For example, a significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.

Share Repurchase Program. We expect continued moderated share repurchase activity for the remainder of 2015 due to the acquisition of Catamaran. For more information on our share repurchase program, see Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

Dividends. In June 2015, our Board increased our quarterly cash dividend to shareholders to an annual dividend rate of $2.00 per share. For more information on our dividend, see Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

Catamaran Acquisition. In March 2015, we entered into an agreement to purchase all of Catamaran’s outstanding common shares for cash. The transaction closed on July 23, 2015. We paid for the acquisition primarily with the proceeds of new indebtedness. For more information about the Catamaran transaction and related debt issuances, see Note 1 and Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

A summary of future obligations under our various contractual obligations and commitments as of December 31, 2014 was disclosed in our 2014 10-K. During the six months endedJune 30, 2015, other than the Catamaran acquisition, there were no material changes to this previously disclosed information outside the ordinary course of business. However, we continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and acquisitions.

RECENTLY ISSUED ACCOUNTING STANDARDS

In May 2014, the FASB issued ASU No. 2014-09 “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 will supersede existing revenue recognition standards with a single model unless those contracts are within the scope of other standards (e.g., an insurance entity’s insurance contracts). The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will

27

be required. Companies can adopt the new standard using either the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. In July 2015, the FASB approved the deferral of ASU 2014-09 for one year and is effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption at the original effective date, interim and annual periods beginning after December 15, 2016, will be permitted. We are currently evaluating the effect of the new revenue recognition guidance.

We have determined that there have been no other recently issued, but not yet adopted, accounting standards that will have a material impact on our Condensed Consolidated Financial Statements.

CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates and this difference would be reported in our current operations.

Our critical accounting estimates include medical costs payable, revenues, goodwill and intangible assets, investments, income taxes and contingent liabilities. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our 2014 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in our 2014 10-K.

FORWARD-LOOKING STATEMENTS

The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements within the meaning of the PSLRA. These statements are intended to take advantage of the “safe harbor” provisions of the PSLRA. Generally the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “plan,” “project,” “should” and similar expressions identify forward-looking statements, which generally are not historical in nature. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. We caution that actual results could differ materially from those that management expects, depending on the outcome of certain factors.

Some factors that could cause actual results to differ materially from results discussed or implied in the forward-looking statements include: our ability to effectively estimate, price for and manage our medical costs, including the impact of any new coverage requirements; new laws or regulations, or changes in existing laws or regulations, or their enforcement or application, including increases in medical, administrative, technology or other costs or decreases in enrollment resulting from U.S., Brazilian and other jurisdictions regulations affecting the health care industry; assessments for insolvent payers under state guaranty fund laws; our ability to achieve improvement in CMS star ratings and other quality scores that impact revenue; reductions in revenue or delays to cash flows received under Medicare, Medicaid and TRICARE programs, including sequestration and the effects of a prolonged U.S. government shutdown or debt ceiling constraints; changes in Medicare, including changes in payment methodology, the CMS star ratings program or the application of risk adjustment data validation audits; our participation in federal and state health insurance exchanges which entail uncertainties associated with mix and volume of business; cyber-attacks or other privacy or data security incidents; failure to comply with privacy and data security regulations; regulatory and other risks and uncertainties of the pharmacy benefits management industry; competitive pressures, which could affect our ability to maintain or increase our market share; challenges to our public sector contract awards; our ability to execute contracts on competitive terms with physicians, hospitals and other service providers; failure to achieve targeted operating cost productivity improvements, including savings resulting from technology enhancement and administrative modernization; increases in costs and other liabilities associated with increased litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of acquisitions and other strategic transactions, including our acquisition of Catamaran; fluctuations in foreign currency exchange rates on our reported shareholders equity and results of operations; downgrades in our credit ratings; adverse economic conditions, including decreases in enrollment resulting from increases in the unemployment rate and commercial attrition; the performance of our investment portfolio; impairment of the value of our goodwill and intangible assets in connection with dispositions or if estimated future results do not adequately support goodwill and intangible assets recorded for our existing businesses or the businesses that we acquire; increases in health care costs resulting from large-scale medical emergencies; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; and our ability to obtain sufficient funds from our regulated subsidiaries or the debt or capital markets to

28

fund our obligations, to maintain our debt to total capital ratio at targeted levels, to maintain our quarterly dividend payment cycle or to continue repurchasing shares of our common stock.

This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain risk factors that may affect our business operations, financial condition and results of operations, in our other periodic and current filings with the SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Any or all forward-looking statements we make may turn out to be wrong, and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual future results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by applicable securities laws.

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary market risks are exposures to changes in interest rates that impact our investment income and interest expense and the fair value of certain of our fixed-rate investments and debt, as well as foreign currency exchange rate risk of the U.S. dollar primarily to the Brazilian real.

We manage exposure to market interest rates by diversifying investments across different fixed income market sectors and debt across maturities, as well as by endeavoring to match our floating-rate assets and liabilities over time, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale securities are reported in comprehensive income.

The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June 30, 2015 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):

	June 30, 2015
Increase (Decrease) in Market Interest Rate	Investment Income Per Annum (a)			Interest Expense Per Annum (a)			Fair Value of Financial Assets (b)			Fair Value of Financial Liabilities
2 %	$	197		$	263		$	(1,374	)	$	(1,657	)
1	98			131			(696		)	(909		)
(1)	(61		)	(24		)	645			1,108
(2)	nm			nm			1,114			2,464

nm = not meaningful

(a) Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2015, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income or interest expense as the rate cannot fall below zero and thus the 200 basis point reduction is not meaningful.

(b) As of June 30, 2015, some of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does not reflect the full 200 basis point reduction.

We have an exposure to changes in the value of the Brazilian real to the U.S. dollar in translation of Amil’s operating results at the average exchange rate over the accounting period, and Amil’s assets and liabilities at the spot rate at the end of the accounting period. The gains or losses resulting from translating foreign assets and liabilities into U.S. dollars are included in shareholders’ equity and comprehensive income.

An appreciation of the U.S. dollar against the Brazilian real reduces the carrying value of the net assets denominated in Brazilian real. For example, as of June 30, 2015, a hypothetical 10% and 25% increase in the value of the U.S. dollar against the Brazilian real would have caused a reduction in net assets of approximately $370 million and $815 million, respectively. We manage exposure to foreign currency risk by conducting our international business operations primarily in their functional currencies.

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

29

In connection with the filing of this Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2015. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2015.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

A description of our legal proceedings is included in and incorporated by reference to Note 10 of Notes to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2014 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2014 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or future results.

There have been no material changes to the risk factors disclosed in our 2014 10-K.

ITEM 2.    UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities (a)

Second Quarter 2015

For the Month Ended	Total Number of Shares Purchased (b)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b)	Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs
	(in millions)			(in millions)	(in millions)
April 30, 2015	—	$	—	—	63
May 31, 2015	—	—		—	63
June 30, 2015	—	—		—	63
Total	—	$	—	—

(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates periodically. In June 2014, the Board renewed our share repurchase program with an authorization to repurchase up to 100 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the program.

(b) During the three months ended June 30, 2015, we repurchased 0.5 million shares at an average price of $117 per share.

30

ITEM 6. EXHIBITS**

The following exhibits are filed in response to Item 601 of Regulation S-K.

3.1	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2	Bylaws of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
4.1	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
4.2	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)
4.3	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007)
4.4	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
*10.1	Amended and Restated UnitedHealth Group Incorporated 2011 Stock Incentive Plan, effective June 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 5, 2015)
12.1	Computation of Ratio of Earnings to Fixed Charges
31.1	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101	The following materials from UnitedHealth Group Incorporated’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed on July 29, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Shareholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.

 ________________

*	Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.
**	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UNITEDHEALTH GROUP INCORPORATED

/s/    STEPHEN J. HEMSLEY	Chief Executive Officer (principal executive officer)	Dated:	July 29, 2015
Stephen J. Hemsley
/s/    DAVID S. WICHMANN	President and Chief Financial Officer (principal financial officer)	Dated:	July 29, 2015
David S. Wichmann
/S/    ERIC S. RANGEN	Senior Vice President and Chief Accounting Officer (principal accounting officer)	Dated:	July 29, 2015
Eric S. Rangen

32

EXHIBIT INDEX**

The following exhibits are filed in response to Item 601 of Regulation S-K.

3.1	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2	Bylaws of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
4.1	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
4.2	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)
4.3	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007)
4.4	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
*10.1	Amended and Restated UnitedHealth Group Incorporated 2011 Stock Incentive Plan, effective June 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 5, 2015)
12.1	Computation of Ratio of Earnings to Fixed Charges
31.1	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101	The following materials from UnitedHealth Group Incorporated’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed on July 29, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Shareholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.

 ________________

*	Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.
**	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.

33

EX-12.1

EXHIBIT 12.1

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

	Three Months Ended June 30,				Six Months Ended June 30,
(dollars in millions)	2015		2014		2015		2014
Earnings before income taxes	$	2,744	$	2,397	$	5,234	$	4,291
Fixed charges	190		188		381		380
Total earnings available for fixed charges	$	2,934	$	2,585	$	5,615	$	4,671
Fixed Charges:
Interest expense	$	151	$	155	$	301	$	315
Interest component of rental payments	39		33		80		65
Total fixed charges	$	190	$	188	$	381	$	380
Ratio of earnings to fixed charges	15.4		13.8		14.7		12.3

The ratio of earnings to fixed charges is computed by dividing total earnings available for fixed charges by the fixed charges. For purposes of computing this ratio, fixed charges consist of interest expense plus the interest factor in rental expense.

EX-31.1

EXHIBIT 31.1

CERTIFICATIONS PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

Certification of Principal Executive Officer

 I, Stephen J. Hemsley, certify that:

1. I have reviewed this report on Form 10-Q of UnitedHealth Group Incorporated (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

July 29, 2015	/s/    STEPHEN J. HEMSLEY
	Stephen J. Hemsley Chief Executive Officer

Certification of Principal Financial Officer

I, David S. Wichmann, certify that:

1. I have reviewed this report on Form 10-Q of UnitedHealth Group Incorporated (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

July 29, 2015	/s/    DAVID S. WICHMANN
	David S. Wichmann President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Certification of Principal Executive Officer

In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen J. Hemsley, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

July 29, 2015	/s/    STEPHEN J. HEMSLEY
	Stephen J. Hemsley Chief Executive Officer

Certification of Principal Financial Officer

In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David S. Wichmann, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

July 29, 2015	/s/    DAVID S. WICHMANN
	David S. Wichmann President and Chief Financial Officer

XML

Fair Value Fair Value Inputs Assets Quantitative Information (Details) - Jun. 30, 2015 $ in Millions	USD ($)
Venture Capital Funds [Member] | Market Approach Valuation Technique [Member] | Comparable Companies [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Available-for-sale Securities	$ 268
Venture Capital Funds [Member] | Market Approach Valuation Technique [Member] | Recent Transactions [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Available-for-sale Securities	$ 51
Minimum [Member] | Comparable Companies [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Fair Value Inputs, Revenue Multiple	1.0
Fair Value Inputs, Earnings before Interest, Taxes, Depreciation, and Amortization Multiple	8.0
Maximum [Member] | Comparable Companies [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Fair Value Inputs, Revenue Multiple	5.0
Fair Value Inputs, Earnings before Interest, Taxes, Depreciation, and Amortization Multiple	10.0
Unobservable Inputs (Level 3) [Member] | Equity Securities [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Available-for-sale Securities	$ 319

XML

Share-Based Compensation Other Share-Based Compensation Data (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense, before tax	$ 86	$ 83	$ 211	$ 188
Share-based compensation expense, net of tax effects	76	71	177	157
Income tax benefit realized from share-based award exercises	36	$ 24	174	$ 143
Unrecognized compensation expense related to share awards	$ 551		$ 551
Weighted-average years to recognize compensation expense			1 year 4 months 24 days
Stock Options and SARs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of shares granted, per share	$ 21	$ 19	$ 23	$ 22
Total intrinsic value of stock options and SARs exercised	$ 107	$ 74	$ 328	$ 286
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (per share)	$ 118	$ 80	$ 109	$ 70
Total fair value of restricted shares vested	$ 12	$ 9	$ 407	$ 423

XML

Commercial Paper and Long-Term Debt Fair Value Hedges Effect of Changes in Fair Value Hedges on Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Net impact on the Company’s Consolidated Statements of Operations	$ 0	$ 0	$ 0	$ 0
Interest Rate Swap [Member] | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Hedge - interest rate swap (loss) gain recognized in interest expense	(208)	67	14	133
Debt [Member] | Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Hedged item - long-term debt gain (loss) recognized in interest expense	$ 208	$ (67)	$ (14)	$ (133)

XML

Commercial Paper and Long-Term Debt Subsequent Event July Debt Issuance (Details) - USD ($) $ in Millions	Jul. 29, 2015	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Par Value		$ 18,017	$ 17,347
Subsequent Event [Member]
Debt Instrument [Line Items]
Par Value	$ 10,500
Floating Rate Unsecured Notes due January 2017 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Par Value	$ 750
1.4500% Senior Unsecured Notes due July 2017 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.45%
Par Value	$ 750
1.900% Senior Unsecured Notes due July 2018 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.90%
Par Value	$ 1,500
2.700% Senior Unsecured Notes due July 2020 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.70%
Par Value	$ 1,500
3.350% Senior Unsecured Notes due July 2022 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.35%
Par Value	$ 1,000
3.750% Senior Unsecured Notes due July 2025 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.75%
Par Value	$ 2,000
4.625% Senior Unsecured Notes due July 2035 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.625%
Par Value	$ 1,000
4.750% Senior Unsecured Notes due July 2045 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Par Value	$ 2,000
Delayed Draw Term Loan [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Par Value	1,500
Commercial Paper [Member]
Debt Instrument [Line Items]
Par Value		$ 1,407	$ 321
Commercial Paper [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Par Value	$ 2,400

XML

Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Debt Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	$ 6,332	$ 3,980
Less Than 12 Months, Gross Unrealized Losses	(61)	(24)
Greater Than 12 Months, Fair Value	454	949
Greater Than 12 Months, Gross Unrealized Losses	(10)	(17)
Total, Fair Value	6,786	4,929
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(71)	(41)
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	529	420
Less Than 12 Months, Gross Unrealized Losses	(4)	(1)
Total, Fair Value	529	420
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(4)	(1)
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	1,561	711
Less Than 12 Months, Gross Unrealized Losses	(16)	(4)
Greater Than 12 Months, Fair Value	22	99
Greater Than 12 Months, Gross Unrealized Losses	(1)	(1)
Total, Fair Value	1,583	810
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(17)	(5)
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	3,126	2,595
Less Than 12 Months, Gross Unrealized Losses	(27)	(17)
Greater Than 12 Months, Fair Value	229	464
Greater Than 12 Months, Gross Unrealized Losses	(4)	(9)
Total, Fair Value	3,355	3,059
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(31)	(26)
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	752
Less Than 12 Months, Gross Unrealized Losses	(10)
Greater Than 12 Months, Fair Value	126	272
Greater Than 12 Months, Gross Unrealized Losses	(4)	(5)
Total, Fair Value	878	272
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(14)	(5)
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	364	254
Less Than 12 Months, Gross Unrealized Losses	(4)	(2)
Greater Than 12 Months, Fair Value	77	114
Greater Than 12 Months, Gross Unrealized Losses	(1)	(2)
Total, Fair Value	441	368
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(5)	(4)
Equity Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	148	107
Less Than 12 Months, Gross Unrealized Losses	(9)	(6)
Greater Than 12 Months, Fair Value	82	88
Greater Than 12 Months, Gross Unrealized Losses	(29)	(19)
Total, Fair Value	230	195
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ (38)	$ (25)

XML

Segment Financial Information (Narrative) (Details)	6 Months Ended
	Jun. 30, 2015
Statement [Line Items]
Number of Reportable Segments	4

XML

Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2015

Dividends Declared [Table Text Block]

The following table provides details of the Company’s 2015 dividend payments:

Payment Date	Amount per Share		Total Amount Paid
			(in millions)
March 24, 2015	$	0.3750	$	357
June 24, 2015	0.5000		476

XML

Shareholders' Equity Dividends Paid (Details) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended
	Jun. 24, 2015	Mar. 24, 2015	Jun. 30, 2015	Jun. 30, 2014
Class of Stock [Line Items]
Common Stock, Dividends, Per Share, Cash Paid	$ 0.5000	$ 0.3750
Payments of Ordinary Dividends, Common Stock	$ 476	$ 357	$ 833	$ 642

XML

Medical Costs Reserve Development (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Liability for Claims and Claims Adjustment Expense [Line Items]
Related to Prior Years	$ (10)	$ 40	$ 130	$ 260
Related to Current Years	$ 100	$ 90

XML

Fair Value (Financial Assets and Liabilities, Excluding AARP, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities - held-to-maturity	$ 546	$ 495
Held-to-maturity Securities, Fair Value	549	497
Long-term Debt, Gross	17,926	17,256
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	549	497
Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	277	226
Fair Value, Measurements, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	10	10
Fair Value, Measurements, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	262	261
U.S. Government and Agency Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	185	180
U.S. Government and Agency Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	185	180
U.S. Government and Agency Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	0	0
U.S. Government and Agency Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	0	0
State and Municipal Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	15	19
State and Municipal Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	0	0
State and Municipal Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	0	0
State and Municipal Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	15	19
Corporate Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	349	298
Corporate Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	92	46
Corporate Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	10	10
Corporate Obligations [Member] | Fair Value, Measurements, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held-to-maturity Securities, Fair Value	247	242
Long-term debt and other financing obligations | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	17,755	18,863
Long-term debt and other financing obligations | Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	0	0
Long-term debt and other financing obligations | Fair Value, Measurements, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	17,755	18,863
Long-term debt and other financing obligations | Fair Value, Measurements, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	0	0
Other Assets [Member] | Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Assets, Fair Value Disclosure	473	478
Other Assets [Member] | Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Assets, Fair Value Disclosure	0	0
Other Assets [Member] | Fair Value, Measurements, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Assets, Fair Value Disclosure	473	478
Other Assets [Member] | Fair Value, Measurements, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Assets, Fair Value Disclosure	0	0
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities - held-to-maturity	546	495
Carrying (Reported) Amount, Fair Value Disclosure [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities - held-to-maturity	182	178
Carrying (Reported) Amount, Fair Value Disclosure [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities - held-to-maturity	15	19
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities - held-to-maturity	349	298
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Long-term debt and other financing obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Gross	16,664	17,085
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Assets, Fair Value Disclosure	$ 472	$ 484

XML

Share-Based Compensation (Stock Option and SAR Activity) (Details) - Jun. 30, 2015 - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Total
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at the beginning of the period	33
Granted, Shares	8
Exercised, Shares	(6)
Outstanding at the end of the period	35
Exercisable at end of period, Shares	18
Vested and expected to vest end of period, Shares	34
Outstanding at beginning of period, Weighted-Average Exercise Price	$ 53
Granted, Weighted-Average Exercise Price	109
Exercised, Weighted-Average Exercise Price	52
Outstanding at end of period, Weighted-Average Exercise Price	66
Exercisable at end of period, Weighted-Average Exercise Price	47
Vested and expected to vest end of period, Weighted-Average Exercise Price	$ 66
Outstanding at end of period, Weighted Average Remaining Contractual Term (in years)	6 years 2 months 12 days
Exercisable at end of period, Weighted Average Remaining Contractual Term (in years)	3 years 8 months 12 days
Vested and expected to vest end of period, Weighted Average Remaining Contractual Term (in years)	6 years 1 month 6 days
Outstanding at end of period, Aggregate Intrinsic Value	$ 1,971
Exercisable at end of period, Aggregate Intrinsic Value	1,335
Vested and expected to vest end of period, Aggregate Intrinsic Value	$ 1,933

XML

Commercial Paper and Long-Term Debt Fair Value Hedges Statement of Financial Position Location (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Assets, at Fair Value	$ 54	$ 62
Interest Rate Derivative Liabilities, at Fair Value	33	55
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	10,300	10,700
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Assets, at Fair Value	54	62
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member] | Other Liabilities [Member]
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	$ 33	$ 55

XML

Investments (Notes)

6 Months Ended

Jun. 30, 2015

Investments [Abstract]

Investments [Text Block]

Investments

A summary of short-term and long-term investments by major security type is as follows:

(in millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2015
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,859	$	6	$	(4	)	$	1,861
State and municipal obligations	6,196		127		(17		)	6,306
Corporate obligations	7,654		76		(31		)	7,699
U.S. agency mortgage-backed securities	2,091		25		(14		)	2,102
Non-U.S. agency mortgage-backed securities	837		8		(5		)	840
Total debt securities - available-for-sale	18,637		242		(71		)	18,808
Equity securities - available-for-sale	1,559		36		(38		)	1,557
Debt securities - held-to-maturity:
U.S. government and agency obligations	182		3		—			185
State and municipal obligations	15		—		—			15
Corporate obligations	349		—		—			349
Total debt securities - held-to-maturity	546		3		—			549
Total investments	$	20,742	$	281	$	(109	)	$	20,914
December 31, 2014
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,614	$	7	$	(1	)	$	1,620
State and municipal obligations	6,456		217		(5		)	6,668
Corporate obligations	7,241		112		(26		)	7,327
U.S. agency mortgage-backed securities	2,022		39		(5		)	2,056
Non-U.S. agency mortgage-backed securities	872		12		(4		)	880
Total debt securities - available-for-sale	18,205		387		(41		)	18,551
Equity securities - available-for-sale	1,511		36		(25		)	1,522
Debt securities - held-to-maturity:
U.S. government and agency obligations	178		2		—			180
State and municipal obligations	19		—		—			19
Corporate obligations	298		—		—			298
Total debt securities - held-to-maturity	495		2		—			497
Total investments	$	20,211	$	425	$	(66	)	$	20,570

The amortized cost and fair value of available-for-sale debt securities as of June 30, 2015, by contractual maturity, were as follows:

(in millions)	Amortized Cost		Fair Value
Due in one year or less	$	2,010	$	2,014
Due after one year through five years	6,943		7,009
Due after five years through ten years	5,016		5,067
Due after ten years	1,740		1,776
U.S. agency mortgage-backed securities	2,091		2,102
Non-U.S. agency mortgage-backed securities	837		840
Total debt securities - available-for-sale	$	18,637	$	18,808

The amortized cost and fair value of held-to-maturity debt securities as of June 30, 2015, by contractual maturity, were as follows:

(in millions)	Amortized Cost		Fair Value
Due in one year or less	$	126	$	126
Due after one year through five years	204		205
Due after five years through ten years	106		107
Due after ten years	110		111
Total debt securities - held-to-maturity	$	546	$	549

The fair value of available-for-sale investments with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:

	Less Than 12 Months					12 Months or Greater					Total
(in millions)	Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses
June 30, 2015
Debt securities - available-for-sale:
U.S. government and agency obligations	$	529	$	(4	)	$	—	$	—		$	529	$	(4	)
State and municipal obligations	1,561		(16		)	22		(1		)	1,583		(17		)
Corporate obligations	3,126		(27		)	229		(4		)	3,355		(31		)
U.S. agency mortgage-backed securities	752		(10		)	126		(4		)	878		(14		)
Non-U.S. agency mortgage-backed securities	364		(4		)	77		(1		)	441		(5		)
Total debt securities - available-for-sale	$	6,332	$	(61	)	$	454	$	(10	)	$	6,786	$	(71	)
Equity securities - available-for-sale	$	148	$	(9	)	$	82	$	(29	)	$	230	$	(38	)
December 31, 2014
Debt securities - available-for-sale:
U.S. government and agency obligations	$	420	$	(1	)	$	—	$	—		$	420	$	(1	)
State and municipal obligations	711		(4		)	99		(1		)	810		(5		)
Corporate obligations	2,595		(17		)	464		(9		)	3,059		(26		)
U.S. agency mortgage-backed securities	—		—			272		(5		)	272		(5		)
Non-U.S. agency mortgage-backed securities	254		(2		)	114		(2		)	368		(4		)
Total debt securities - available-for-sale	$	3,980	$	(24	)	$	949	$	(17	)	$	4,929	$	(41	)
Equity securities - available-for-sale	$	107	$	(6	)	$	88	$	(19	)	$	195	$	(25	)

The Company’s unrealized losses from all securities as of June 30, 2015 were generated from approximately 7,100 positions out of a total of 23,000 positions. The Company believes that it will collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor other factors leading to an other-than-temporary impairment (OTTI). As of June 30, 2015, the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.

The Company’s investments in equity securities consist of investments in Brazilian real denominated fixed-income funds, employee savings plan related investments, venture capital funds, and dividend paying stocks. The Company evaluated its investments in equity securities for severity and duration of unrealized loss, overall market volatility and other market factors.

Net realized gains reclassified out of accumulated other comprehensive income were from the following sources:

	Three Months Ended June 30,						Six Months Ended June 30,
(in millions)	2015			2014			2015			2014
Total OTTI	$	(3	)	$	(4	)	$	(4	)	$	(7	)
Portion of loss recognized in other comprehensive income	—			—			—			—
Net OTTI recognized in earnings	(3		)	(4		)	(4		)	(7		)
Gross realized losses from sales	(5		)	(29		)	(11		)	(39		)
Gross realized gains from sales	76			140			86			199
Net realized gains (included in investment and other income on the Condensed Consolidated Statements of Operations)	68			107			71			153
Income tax effect (included in provision for income taxes on the Condensed Consolidated Statements of Operations)	(25		)	(39		)	(26		)	(56		)
Realized gains, net of taxes	$	43		$	68		$	45		$	97

XML

Health Insurance Industry Tax (Details) - Industry Tax [Member] $ in Millions	Jun. 30, 2015 USD ($)
Health Insurance Industry Tax [Line Items]
Accrued Liabilities, Current	$ 1,800
Deferred Costs, Current	$ 900

XML

Investments (Narrative) (Details) - Jun. 30, 2015	positions
Investment [Line Items]
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions	7,100
Total number of security positions	23,000

XML

Basis of Presentation Basis of Presentations (Details) $ in Millions	Jul. 23, 2015 USD ($)	Jul. 29, 2015 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)
Business Acquisition [Line Items]
Par Value			$ 18,017	$ 17,347
Subsequent Event [Member]
Business Acquisition [Line Items]
Par Value		$ 10,500
Subsequent Event [Member] | Catamaran [Member]
Business Acquisition [Line Items]
People Served	35,000,000
Business Acquisition, Percentage of Voting Interests to be Acquired	100.00%
Delayed Draw Term Loan [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Par Value		$ 1,500
Catamaran Outstanding Common Shares [Member] | Subsequent Event [Member] | Catamaran [Member]
Business Acquisition [Line Items]
Payments made to Acquire Businesses, Gross	$ 12,900

XML

Commitments and Contingencies (Details) - California Claims Processing Matter [Member] - USD ($) $ in Millions			1 Months Ended
	Jun. 09, 2014	Jan. 28, 2008	Aug. 31, 2013	Jun. 30, 2015
Loss Contingency [Line Items]
Estimated Largest Aggregate Penalty Issued By Cdi				$ 8.0
CDI aggregate penalty		$ 325.0
California Administrative Law Judge [Member] | Judicial Ruling [Member]
Loss Contingency [Line Items]
Loss Contingency, Damages Awarded, Value			$ 11.5
California Insurance Commissioner [Member] | Judicial Ruling [Member]
Loss Contingency [Line Items]
Loss Contingency, Damages Awarded, Value	$ 174.0

XML

Commercial Paper and Long-Term Debt (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2015 USD ($) banks	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Other Long-term Debt	$ 145	$ 150
Other Long-term Debt, Current	$ 47	$ 34
Commercial Paper [Member]
Debt Instrument [Line Items]
Short-term Debt, Weighted Average Interest Rate	0.30%
Five Year $3.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term Line of Credit	$ 0
Line of Credit, Credit Facility, Maximum Borrowing Capacity	$ 3,000
Number Of Years Of Revolving Bank Credit	5 years
Number of banks that comprise revolving bank credit facility (banks)	23
Maximum percentage of indebtedness to total net capital bank covenant	50.00%
Five Year $3.0 Billion Credit Facility [Member] | Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.00%
Five Year $3.0 Billion Credit Facility [Member] | Maximum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.30%
364 Day $1.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term Line of Credit	$ 0
Line of Credit, Credit Facility, Maximum Borrowing Capacity	$ 1,000
Credit Facility, Number of Days	364 days
Number of banks that comprise revolving bank credit facility (banks) | banks	23
Maximum percentage of indebtedness to total net capital bank covenant	50.00%
364 Day $1.0 Billion Credit Facility [Member] | Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.00%
364 Day $1.0 Billion Credit Facility [Member] | Maximum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.30%
364 Day $2.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term Line of Credit	$ 0
Line of Credit, Credit Facility, Maximum Borrowing Capacity	$ 2,000
Credit Facility, Number of Days	364 days
Number of banks that comprise revolving bank credit facility (banks) | banks	22
Maximum percentage of indebtedness to total net capital bank covenant	50.00%
364 Day $2.0 Billion Credit Facility [Member] | Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.00%
364 Day $2.0 Billion Credit Facility [Member] | Maximum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.30%
Delayed Draw Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Unused Borrowing Capacity, Amount	$ 1,500
Delayed Draw Term Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.00%
Delayed Draw Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.30%

XML

Investments (Short-Term and Long-Term Investments) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Schedule of Investments [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	$ 18,637	$ 18,205
Securities, Available for sale Debt Securities, Gross Unrealized Gains	242	387
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(71)	(41)
Available-for-sale Securities, Debt Securities	18,808	18,551
Available-for-sale Equity Securities, Amortized Cost Basis	1,559	1,511
Securities, Available for sale Equity Securities, Gross Unrealized Gains	36	36
Securities, Available for sale Equity Securities, Gross Unrealized Losses	(38)	(25)
Available-for-sale Securities, Equity Securities	1,557	1,522
Held-to-maturity securities, Amortized Cost	546	495
Securities, Held to maturity, Unrecognized Holding Gain	3	2
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0	0
Held-to-maturity Securities, Fair Value	549	497
Total investments, Amortized Cost	20,742	20,211
Total investments, Gross Unrealized Gains	281	425
Total investments, Gross Unrealized Losses	(109)	(66)
Investments, Fair Value Disclosure	20,914	20,570
Debt Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale Securities, Debt Securities	18,808	18,551
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	1,859	1,614
Securities, Available for sale Debt Securities, Gross Unrealized Gains	6	7
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(4)	(1)
Available-for-sale Securities, Debt Securities	1,861	1,620
Held-to-maturity securities, Amortized Cost	182	178
Securities, Held to maturity, Unrecognized Holding Gain	3	2
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0	0
Held-to-maturity Securities, Fair Value	185	180
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	6,196	6,456
Securities, Available for sale Debt Securities, Gross Unrealized Gains	127	217
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(17)	(5)
Available-for-sale Securities, Debt Securities	6,306	6,668
Held-to-maturity securities, Amortized Cost	15	19
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0	0
Held-to-maturity Securities, Fair Value	15	19
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	7,654	7,241
Securities, Available for sale Debt Securities, Gross Unrealized Gains	76	112
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(31)	(26)
Available-for-sale Securities, Debt Securities	7,699	7,327
Held-to-maturity securities, Amortized Cost	349	298
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0	0
Held-to-maturity Securities, Fair Value	349	298
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	2,091	2,022
Securities, Available for sale Debt Securities, Gross Unrealized Gains	25	39
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(14)	(5)
Available-for-sale Securities, Debt Securities	2,102	2,056
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	837	872
Securities, Available for sale Debt Securities, Gross Unrealized Gains	8	12
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(5)	(4)
Available-for-sale Securities, Debt Securities	$ 840	$ 880

XML

Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Schedule of Investments [Line Items]
Due in one year or less, Amortized Cost	$ 2,010
Due after one year through five years, Amortized Cost	6,943
Due after five years through ten years, Amortized Cost	5,016
Due after ten years, Amortized Cost	1,740
Total debt securities - available-for-sale, Amortized Cost	18,637	$ 18,205
Due in one year or less, Fair Value	2,014
Due after one year through five years, Fair Value	7,009
Due after five years through ten years, Fair Value	5,067
Due after ten years, Fair Value	1,776
Available-for-sale Securities, Debt Securities	18,808	18,551
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	2,091
Total debt securities - available-for-sale, Amortized Cost	2,091	2,022
Mortgage-backed securities, Fair Value	2,102
Available-for-sale Securities, Debt Securities	2,102	2,056
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	837
Total debt securities - available-for-sale, Amortized Cost	837	872
Mortgage-backed securities, Fair Value	840
Available-for-sale Securities, Debt Securities	$ 840	$ 880

XML

Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Notes)

6 Months Ended

Jun. 30, 2015

Basis of Presentation and Significant Accounting Policies [Text Block]

Basis of Presentation

UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health and well-being company dedicated to helping people live healthier lives and making the health system work better for everyone. Through its diversified family of businesses, the Company leverages core competencies in advanced, enabling technology; health care data, information and intelligence; and clinical care management and coordination to help meet the demands of the health system. The Company offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.

The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC (2014 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.

Use of Estimates

These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and revenues, valuation and impairment analysis of goodwill and other intangible assets, estimates of other policy liabilities and other current receivables, valuations of certain investments, and estimates and judgments related to income taxes and contingent liabilities. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.

The accounting policies disclosed in Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the 2014 10-K remain unchanged.

Subsequent Events

On July 1, 2015, UnitedHealth Group Incorporated changed its state of incorporation from Minnesota to Delaware pursuant to a plan of conversion. The reincorporation was approved by the Company’s shareholders at its 2015 Annual Meeting of Shareholders held on June 1, 2015. Upon reincorporation, the affairs of UnitedHealth Group Incorporated became subject to the Delaware General Corporation Law, a new certificate of incorporation and new bylaws, and each previously outstanding share of UnitedHealth Group Incorporated’s common stock as a Minnesota corporation (UNH Minnesota) converted into an outstanding share of common stock of UnitedHealth Group Incorporated as a Delaware corporation after the reincorporation (UNH Delaware). The reincorporation was a tax-free reorganization under the U.S. Internal Revenue Code and did not affect the Company’s business operations.

On July 23, 2015, the Company acquired all of the outstanding common shares of Catamaran Corporation (Catamaran) for $12.9 billion in cash and funded Catamaran’s payoff of its outstanding debt and credit facility in connection with the closing. The Company drew its $1.5 billion delayed draw term loan and issued commercial paper and senior unsecured notes to fund the Company’s purchase of Catamaran; see Note 7 of Notes to the Condensed Consolidated Financial Statements for detail on the related July 2015 debt issuance. Catamaran offers retail pharmacy network management, mail service pharmacy, pharmacy claims management and patient-centric specialty pharmacy services to a broad client portfolio, including health plans and employers serving 35 million people, and provides health care information technology solutions to the pharmacy benefits management industry. This acquisition diversifies OptumRx’s customer and business mix, while accelerating its technology leadership and flexible service offerings. As the Catamaran acquisition occurred in the third quarter of 2015, it is not yet practicable to provide disclosures related to the purchase price allocation or pro forma information.

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09). ASU 2014-09 will supersede existing revenue recognition standards with a single model unless those contracts are within the scope of other standards (e.g., an insurance entity’s insurance contracts). The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies can adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. In July 2015, the FASB approved the deferral of ASU 2014-09 for one year and it is effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption at the original effective date, interim and annual periods beginning after December 15, 2016, will be permitted. The Company is currently evaluating the effect of the new revenue recognition guidance.

The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements.

XML

Investments (Amortized Cost and Fair Value of Held-To-Maturity Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Schedule of Held-to-maturity Securities [Line Items]
Due in one year or less, Amortized Cost	$ 126
Due after one year through five years, Amortized Cost	204
Due after five years through ten years, Amortized Cost	106
Due after ten years, Amortized Cost	110
Held-to-maturity securities, Amortized Cost	546	$ 495
Due in one year or less, Fair Value	126
Due after one year through five years, Fair Value	205
Due after five years through ten years, Fair Value	107
Due after ten years, Fair Value	111
Total debt securities - held-to-maturity, Fair Value	$ 549	$ 497

XML

Fair Value (Assets and Liabilities measured at fair value on a recurring basis) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 7,887	$ 7,495
Available-for-sale Securities, Debt Securities	18,808	18,551
Available-for-sale Securities, Equity Securities	1,557	1,522
Total assets at fair value	28,306	27,630
Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	18,808	18,551
U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,861	1,620
State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	6,306	6,668
Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	7,699	7,327
U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	2,102	2,056
Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	840	880
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	7,754	7,472
Available-for-sale Securities, Equity Securities	1,226	1,200
Total assets at fair value	10,642	10,101
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,662	1,429
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,650	1,427
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	12	2
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	133	23
Available-for-sale Securities, Equity Securities	12	12
Total assets at fair value	17,261	17,145
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	17,062	17,048
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	211	193
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	6,306	6,668
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	7,609	7,257
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	2,102	2,056
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	834	874
Fair Value, Measurements, Recurring [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	205	415
Other Investments	85	81
Total assets at fair value	2,863	2,962
Other liabilities	10	18
Fair Value, Measurements, Recurring [Member] | Debt Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	2,573	2,466
Fair Value, Measurements, Recurring [Member] | U.S. Government and Agency Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	595	654
Fair Value, Measurements, Recurring [Member] | State and Municipal Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	96	95
Fair Value, Measurements, Recurring [Member] | Corporate Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,287	1,200
Fair Value, Measurements, Recurring [Member] | U.S. Agency Mortgage-Backed Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	400	340
Fair Value, Measurements, Recurring [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	195	177
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	205	415
Other Investments	0	0
Total assets at fair value	636	824
Other liabilities	4	5
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	431	409
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	431	409
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Fair Value, Measurements, Recurring [Member] | Other Observable Inputs (Level 2) [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Other Investments	85	81
Total assets at fair value	2,227	2,138
Other liabilities	6	13
Fair Value, Measurements, Recurring [Member] | Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	2,142	2,057
Fair Value, Measurements, Recurring [Member] | Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	164	245
Fair Value, Measurements, Recurring [Member] | Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	96	95
Fair Value, Measurements, Recurring [Member] | Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,287	1,200
Fair Value, Measurements, Recurring [Member] | Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	400	340
Fair Value, Measurements, Recurring [Member] | Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | AARP Program [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	$ 195	$ 177

XML

Share-Based Compensation (Restricted Share Activity) (Details) - Jun. 30, 2015 - Restricted Stock [Member] - $ / shares shares in Millions	Total
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at beginning of period, Shares	9
Granted, Shares	2
Vested	(4)
Nonvested at end of period, Shares	7
Nonvested at beginning of period, Weighted-Average Grant Date Fair Value per Share	$ 61
Weighted-average grant date fair value (per share)	109
Vested, Weighted Average Grant Date Fair Value	57
Nonvested at end of period, Weighted-Average Grant Date Fair Value per Share	$ 79

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 7,887	$ 7,495
Short-term investments	1,915	1,741
Accounts receivable, net	6,034	4,252
Other current receivables, net	6,160	5,498
Assets under management	2,863	2,962
Deferred income taxes	514	556
Prepaid expenses and other current assets	2,193	1,052
Total current assets	27,566	23,556
Long-term investments	18,996	18,827
Property, equipment and capitalized software, net	4,473	4,418
Goodwill	34,154	32,940
Other intangible assets, net	3,316	3,669
Other assets	2,918	2,972
Total assets	91,423	86,382
Current liabilities:
Medical costs payable	13,867	12,040
Accounts payable and accrued liabilities	10,901	9,247
Other policy liabilities	6,772	5,965
Commercial paper and current maturities of long-term debt	2,693	1,399
Unearned revenues	1,508	1,972
Total current liabilities	35,741	30,623
Long-term debt, less current maturities	15,378	16,007
Future policy benefits	2,491	2,488
Deferred income taxes	1,877	2,065
Other liabilities	1,301	1,357
Total liabilities	56,788	$ 52,540
Commitments and contingencies (Note 10)
Redeemable noncontrolling interests	1,615	$ 1,388
Shareholders' equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value - 3,000 shares authorized; 952 and 954 issued and outstanding	10	10
Additional paid in capital	55	0
Retained earnings	35,262	33,836
Accumulated other comprehensive loss	(2,307)	(1,392)
Total shareholders' equity	33,020	32,454
Total liabilities and shareholders’ equity	$ 91,423	$ 86,382

XML

Commercial Paper and Long-Term Debt (Details) - USD ($) $ in Millions		Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Par Value		$ 18,017	$ 17,347
Carrying Value		17,926	17,256
Fair Value		19,017	19,034
Commercial Paper [Member]
Debt Instrument [Line Items]
Par Value		1,407	321
Commercial Paper		1,407	321
Fair Value		$ 1,407	321
4.875% Notes Due March 2015 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		4.875%
Par Value	[1]	$ 0	416
Carrying Value	[1]	0	419
Fair Value	[1]	$ 0	419
0.850% Notes due October 2015 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		0.85%
Par Value	[1]	$ 625	625
Carrying Value	[1]	625	625
Fair Value	[1]	$ 625	627
5.375% Notes Due March 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5.375%
Par Value	[1]	$ 601	601
Carrying Value	[1]	614	623
Fair Value	[1]	$ 620	634
1.875% Notes Due November 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.875%
Par Value	[1]	$ 400	400
Carrying Value	[1]	399	397
Fair Value	[1]	$ 405	406
5.360% Notes Due November 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5.36%
Par Value		$ 95	95
Carrying Value		95	95
Fair Value		$ 101	103
6.000% Notes Due June 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Par Value	[1]	$ 441	441
Carrying Value	[1]	463	466
Fair Value	[1]	$ 480	489
1.400% Notes due October 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.40%
Par Value	[1]	$ 625	625
Carrying Value	[1]	621	616
Fair Value	[1]	$ 626	624
6.000% Notes Due November 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Par Value	[1]	$ 156	156
Carrying Value	[1]	163	164
Fair Value	[1]	$ 174	175
1.400% Notes Due December 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.40%
Par Value	[1]	$ 750	750
Carrying Value	[1]	750	745
Fair Value	[1]	$ 749	749
6.000% Notes Due February 2018 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Par Value	[1]	$ 1,100	1,100
Carrying Value	[1]	1,111	1,106
Fair Value	[1]	$ 1,223	1,238
1.625% Notes Due March 2019 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.625%
Par Value	[1]	$ 500	500
Carrying Value	[1]	499	496
Fair Value	[1]	$ 494	493
2.300% Notes Due December 2019 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		2.30%
Par Value	[1]	$ 500	500
Carrying Value	[1]	499	496
Fair Value	[1]	$ 501	502
3.875% Notes Due October 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.875%
Par Value	[1]	$ 450	450
Carrying Value	[1]	451	450
Fair Value	[1]	$ 481	477
4.700% Notes Due February 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		4.70%
Par Value	[1]	$ 400	400
Carrying Value	[1]	413	413
Fair Value	[1]	$ 441	450
3.375% Notes Due November 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.375%
Par Value	[1]	$ 500	500
Carrying Value	[1]	495	496
Fair Value	[1]	$ 514	519
2.875% Notes Due December 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		2.875%
Par Value	[1]	$ 750	750
Carrying Value	[1]	747	748
Fair Value	[1]	$ 750	759
2.875% Notes Due March 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		2.875%
Par Value	[1]	$ 1,100	1,100
Carrying Value	[1]	1,043	1,042
Fair Value	[1]	$ 1,068	1,104
0.000% Notes Due November 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		0.00%
Par Value		$ 15	15
Carrying Value		10	10
Fair Value		$ 11	11
2.750% Notes due February 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		2.75%
Par Value	[1]	$ 625	625
Carrying Value	[1]	602	604
Fair Value	[1]	$ 598	613
2.875% Notes due March 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		2.875%
Par Value	[1]	$ 750	750
Carrying Value	[1]	771	777
Fair Value	[1]	$ 722	745
5.800% Notes Due March 2036 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5.80%
Par Value		$ 850	850
Carrying Value		845	845
Fair Value		$ 988	1,052
6.500% Notes Due June 2037 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.50%
Par Value		$ 500	500
Carrying Value		495	495
Fair Value		$ 631	670
6.625% Notes Due November 2037 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.625%
Par Value		$ 650	650
Carrying Value		646	646
Fair Value		$ 833	888
6.875% Notes Due February 2038 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.875%
Par Value		$ 1,100	1,100
Carrying Value		1,085	1,085
Fair Value		$ 1,447	1,544
5.700% Notes Due October 2040 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5.70%
Par Value		$ 300	300
Carrying Value		298	298
Fair Value		$ 351	378
5.950% Notes Due February 2041 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5.95%
Par Value		$ 350	350
Carrying Value		348	348
Fair Value		$ 417	455
4.625% Notes Due November 2041 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		4.625%
Par Value		$ 600	600
Carrying Value		593	593
Fair Value		$ 599	646
4.375% Notes Due March 2042 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		4.375%
Par Value		$ 502	502
Carrying Value		486	486
Fair Value		$ 487	536
3.950% Notes due October 2042 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.95%
Par Value		$ 625	625
Carrying Value		612	611
Fair Value		$ 565	621
4.250% Notes due March 2043 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		4.25%
Par Value		$ 750	750
Carrying Value		740	740
Fair Value		$ 709	$ 786

[1] Fixed-rate debt instruments hedged with interest rate swap contracts. See below for more information on the Company’s interest rate swaps.

XML

Condesned Consolidated Statements of Changes in Shareholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Net Unrealized Gains (Losses) on Investments [Member]	Foreign Currency Translation (Losses) Gains [Member]
Balance at Dec. 31, 2013	$ 32,149	$ 10	$ 0	$ 33,047	$ 54	$ (962)
Balance (in shares) at Dec. 31, 2013		988
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	2,507			2,507
Other comprehensive income (loss)	618				208	410
Issuances of common shares, and related tax effects (in shares)		10
Issuances of common shares, and related tax effects	23	$ 0	23
Share-based compensation, and related tax benefits	217		217
Common share repurchases (in shares)		(25)
Common share repurchases	(1,937)	$ 0	(240)	(1,697)
Cash dividends paid on common shares	(642)			(642)
Balance (in shares) at Jun. 30, 2014		973
Balance at Jun. 30, 2014	32,935	$ 10	0	33,215	262	(552)
Balance at Dec. 31, 2014	$ 32,454	$ 10	0	33,836	223	(1,615)
Balance (in shares) at Dec. 31, 2014	954	954
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 2,998			2,998
Other comprehensive income (loss)	(915)				(119)	(796)
Issuances of common shares, and related tax effects (in shares)		7
Issuances of common shares, and related tax effects	23	$ 0	23
Share-based compensation, and related tax benefits	319		319
Noncontrolling interests fair value and other adjustments	$ (73)		(73)
Common share repurchases (in shares)	(9)	(9)
Common share repurchases	$ (953)	$ 0	(214)	(739)
Cash dividends paid on common shares	$ (833)			(833)
Balance (in shares) at Jun. 30, 2015	952	952
Balance at Jun. 30, 2015	$ 33,020	$ 10	$ 55	$ 35,262	$ 104	$ (2,411)

XML

Fair Value (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Fair Value [Line Items]
Transfers from level 1 to level 2-Assets	$ 0	$ 0
Transfers from level 1 to level 2-Liabilities	0	0
Transfer from level 2 to level 1-Assets	0	0
Transfer from level 2 to level 1-Liabilities	0	0
Transfers Into Level 3	0	0
Transfers out of Level 3	0	0
Fair Value, Measurements, Nonrecurring [Member]
Fair Value [Line Items]
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis	0	$ 0
Fair Value, Measurements, Recurring [Member] | Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value [Line Items]
Available-for-sale Securities	$ 84

XML

Medicare Part D Pharmacy Benefits (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Other Current Receivables and Other Policy Liabilities Associated with Medicare Part D Program [Table Text Block]

The Condensed Consolidated Balance Sheets include the following amounts associated with the Medicare Part D program:

	June 30, 2015						December 31, 2014
(in millions)	Subsidies		Drug Discount		Risk-Share		Subsidies		Drug Discount		Risk-Share
Other current receivables	$	1,776	$	266	$	20	$	1,801	$	719	$	20
Other policy liabilities	—		164		—		—		302		—

XML

Fair Value (Financial Assets and Liabilities, Excluding AARP, Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 7,887	$ 7,495
Available-for-sale Securities, Debt Securities	18,808	18,551
Available-for-sale Securities, Equity Securities	1,557	1,522
Interest rate swap assets	54	62
Total assets at fair value	$ 28,306	$ 27,630
Percentage of total assets at fair value	100.00%	100.00%
Interest rate swap liabilities	$ 33	$ 55
Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	18,808	18,551
U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,861	1,620
State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	6,306	6,668
Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	7,699	7,327
U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	2,102	2,056
Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	840	880
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	7,754	7,472
Available-for-sale Securities, Equity Securities	1,226	1,200
Interest rate swap assets	0	0
Total assets at fair value	$ 10,642	$ 10,101
Percentage of total assets at fair value	38.00%	37.00%
Interest rate swap liabilities	$ 0	$ 0
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,662	1,429
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	1,650	1,427
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	12	2
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	133	23
Available-for-sale Securities, Equity Securities	12	12
Interest rate swap assets	54	62
Total assets at fair value	$ 17,261	$ 17,145
Percentage of total assets at fair value	61.00%	62.00%
Interest rate swap liabilities	$ 33	$ 55
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	17,062	17,048
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	211	193
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	6,306	6,668
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	7,609	7,257
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	2,102	2,056
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	834	874
Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Available-for-sale Securities, Equity Securities	319	310
Interest rate swap assets	0	0
Total assets at fair value	$ 403	$ 384
Percentage of total assets at fair value	1.00%	1.00%
Interest rate swap liabilities	$ 0	$ 0
Unobservable Inputs (Level 3) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	84	74
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	78	68
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	0	0
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Debt Securities	$ 6	$ 6

XML

Commercial Paper and Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2015

Debt Instrument [Line Items]

Commercial Paper and Long-Term Debt [Table Text Block]

Commercial paper and senior unsecured long-term debt consisted of the following:

	June 30, 2015						December 31, 2014
(in millions, except percentages)	Par Value		Carrying Value		Fair Value		Par Value		Carrying Value		Fair Value
Commercial paper	$	1,407	$	1,407	$	1,407	$	321	$	321	$	321
4.875% notes due March 2015 (a)	—		—		—		416		419		419
0.850% notes due October 2015 (a)	625		625		625		625		625		627
5.375% notes due March 2016 (a)	601		614		620		601		623		634
1.875% notes due November 2016 (a)	400		399		405		400		397		406
5.360% notes due November 2016	95		95		101		95		95		103
6.000% notes due June 2017 (a)	441		463		480		441		466		489
1.400% notes due October 2017 (a)	625		621		626		625		616		624
6.000% notes due November 2017 (a)	156		163		174		156		164		175
1.400% notes due December 2017 (a)	750		750		749		750		745		749
6.000% notes due February 2018 (a)	1,100		1,111		1,223		1,100		1,106		1,238
1.625% notes due March 2019 (a)	500		499		494		500		496		493
2.300% notes due December 2019 (a)	500		499		501		500		496		502
3.875% notes due October 2020 (a)	450		451		481		450		450		477
4.700% notes due February 2021 (a)	400		413		441		400		413		450
3.375% notes due November 2021 (a)	500		495		514		500		496		519
2.875% notes due December 2021 (a)	750		747		750		750		748		759
2.875% notes due March 2022 (a)	1,100		1,043		1,068		1,100		1,042		1,104
0.000% notes due November 2022	15		10		11		15		10		11
2.750% notes due February 2023 (a)	625		602		598		625		604		613
2.875% notes due March 2023 (a)	750		771		722		750		777		745
5.800% notes due March 2036	850		845		988		850		845		1,052
6.500% notes due June 2037	500		495		631		500		495		670
6.625% notes due November 2037	650		646		833		650		646		888
6.875% notes due February 2038	1,100		1,085		1,447		1,100		1,085		1,544
5.700% notes due October 2040	300		298		351		300		298		378
5.950% notes due February 2041	350		348		417		350		348		455
4.625% notes due November 2041	600		593		599		600		593		646
4.375% notes due March 2042	502		486		487		502		486		536
3.950% notes due October 2042	625		612		565		625		611		621
4.250% notes due March 2043	750		740		709		750		740		786
Total commercial paper and long-term debt	$	18,017	$	17,926	$	19,017	$	17,347	$	17,256	$	19,034

(a) Fixed-rate debt instruments hedged with interest rate swap contracts. See below for more information on the Company’s interest rate swaps.

In July 2015, the Company issued commercial paper and senior unsecured notes and drew on its delayed draw term loan. The proceeds of these debt issuances were used to fund the Catamaran acquisition. For more detail on the Catamaran acquisition see Note 1 of the Notes to the Condensed Consolidated Financial Statements.

(in millions, except percentages)	Par Value
Floating rate notes due January 2017	$	750
1.450% notes due July 2017	750
1.900% notes due July 2018	1,500
2.700% notes due July 2020	1,500
3.350% notes due July 2022	1,000
3.750% notes due July 2025	2,000
4.625% notes due July 2035	1,000
4.750% notes due July 2045	2,000
Total July 2015 Issuance	$	10,500
Delayed draw term loan	$	1,500
Commercial paper	$	2,400

Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following table summarizes the location and fair value of the interest rate swap fair value hedges on the Company’s Condensed Consolidated Balance Sheet:

Type of Fair Value Hedge	Notional Amount		Fair Value		Balance Sheet Location
	(in billions)		(in millions)
June 30, 2015
Interest rate swap contracts	$	10.3	54		Other assets
			33		Other liabilities
December 31, 2014
Interest rate swap contracts	$	10.7	$	62	Other assets
			55		Other liabilities

Derivative Instruments, Gain (Loss) [Table Text Block]

The following table provides a summary of the effect of changes in fair value of fair value hedges on the Company’s Condensed Consolidated Statements of Operations:

	Three Months Ended June 30,						Six Months Ended  June 30,
(in millions)	2015			2014			2015			2014
Hedge - interest rate swap (loss) gain recognized in interest expense	$	(208	)	$	67		$	14		$	133
Hedged item - long-term debt gain (loss) recognized in interest expense	208			(67		)	(14		)	(133		)
Net impact on the Company’s Condensed Consolidated Statements of Operations	$	—		$	—		$	—		$	—

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net earnings	$ 2,998	$ 2,507
Noncash items:
Depreciation and amortization	757	724
Deferred income taxes	(30)	(16)
Share-based compensation	211	188
Other, net	(160)	(148)
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable	(1,725)	(2,131)
Other assets	(2,178)	(1,135)
Medical costs payable	1,988	560
Accounts payable and other liabilities	1,809	2,219
Other policy liabilities	208	(218)
Unearned revenues	(446)	(128)
Cash flows from operating activities	3,432	2,422
Investing activities
Purchases of investments	(4,286)	(5,477)
Sales of investments	2,260	4,393
Maturities of investments	1,622	1,544
Cash paid for acquisitions, net of cash assumed	(1,778)	(523)
Purchases of property, equipment and capitalized software	(716)	(716)
Other, net	48	(99)
Cash flows used for investing activities	(2,850)	(878)
Financing activities
Common stock repurchases	(953)	(1,937)
Cash dividends paid	(833)	(642)
Proceeds from common stock issuances	242	267
Repayments of long-term debt	(416)	(172)
Proceeds from (repayments of) commercial paper, net	1,086	(101)
Customer funds administered	941	333
Other, net	(188)	(170)
Cash flows used for financing activities	(121)	(2,422)
Effect of exchange rate changes on cash and cash equivalents	(69)	14
Increase (decrease) in cash and cash equivalents	392	(864)
Cash and cash equivalents, beginning of period	7,495	7,276
Cash and Cash Equivalents, end of period	$ 7,887	$ 6,412

XML

Condensed Consolidated Balance Sheet (Parenthetical) - $ / shares shares in Millions	Jun. 30, 2015	Dec. 31, 2014
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000	3,000
Common stock, shares issued	952	954
Common stock, shares outstanding	952	954
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10	10
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML

Commitments and Contingencies (Notes)

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Commitments and Contingencies

Legal Matters

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims, and claims related to health care benefits coverage and other business practices.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.

Litigation Matters

California Claims Processing Matter.On January 25, 2008, the California Department of Insurance (CDI) issued an Order to Show Cause to PacifiCare Life and Health Insurance Company, a subsidiary of the Company, alleging violations of certain insurance statutes and regulations related to an alleged failure to include certain language in standard claims correspondence, timeliness and accuracy of claims processing, interest payments, care provider contract implementation, care provider dispute resolution and other related matters. Although the Company believes that CDI had never before issued a fine in excess of $8 million, CDI advocated a fine of approximately $325 million in this matter. The matter was the subject of an administrative hearing before a California administrative law judge beginning in December 2009, and in August 2013, the administrative law judge issued a nonbinding proposed decision recommending a fine of $11.5 million. The California Insurance Commissioner rejected the administrative law judge’s recommendation and on June 9, 2014, issued his own decision imposing a fine of approximately $174 million. On July 10, 2014, the Company filed a lawsuit in California state court challenging the Commissioner’s decision. The Company cannot reasonably estimate the range of loss, if any, that may result from this matter given the procedural status of the dispute, the wide range of possible outcomes, the legal issues presented (including the legal basis for the majority of the alleged violations), the inherent difficulty in predicting a regulatory fine in the event of a remand, and the various remedies and levels of judicial review that remain available to the Company.

Government Investigations, Audits and Reviews

The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, the Brazilian national regulatory agency for private health insurance and plans (the Agência Nacional de Saúde Suplementar), state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the Brazilian federal revenue service (the Secretaria da Receita Federal), the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other things, compliance with coding and other requirements under the Medicare risk-adjustment model.

In February 2012, CMS announced a final Risk Adjustment Data Validation (RADV) audit and payment adjustment methodology and that it will conduct RADV audits beginning with the 2011 payment year. These audits involve a review of medical records maintained by care providers and may result in retrospective adjustments to payments made to health plans. CMS has not communicated how the final payment adjustment under its methodology will be implemented.

The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.

Guaranty Fund Assessments

Under state guaranty fund laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies. In 2009, the Pennsylvania Insurance Commissioner placed long term care insurer Penn Treaty Network America Insurance Company and its subsidiary (Penn Treaty), neither of which is affiliated with the Company, in rehabilitation and petitioned a state court for approval to liquidate Penn Treaty. In 2012, the court denied the liquidation petition and ordered the Insurance Commissioner to submit a rehabilitation plan. The court held a hearing on July 13, 2015 to begin its consideration of the latest proposed rehabilitation plan.

If the current proposed rehabilitation plan, which contemplates the partial liquidation of Penn Treaty, is approved by the court, the Company’s insurance entities and other insurers may be required to pay a portion of Penn Treaty’s policyholder claims through state guaranty association assessments in future periods. The Company intends to vigorously challenge the proposed rehabilitation plan. The Company is currently unable to estimate losses or ranges of losses because the Company cannot predict whether, when or to what extent Penn Treaty will ultimately be declared insolvent, the amount of the insolvency, if any, the amount and timing of any associated guaranty fund assessments or the availability and amount of any premium tax and other potential offsets.

XML

Document and Entity Information Document - shares	6 Months Ended
	Jun. 30, 2015	Jul. 24, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entitiy Registrant Name	UNITEDHEALTH GROUP INC
Entitiy Central Index Key	0000731766
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		953,562,580

XML

Segment Financial Information (Notes)

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Segment Financial Information [Text Block]

Segment Financial Information

The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more information on the Company’s segments see Part I, Item I, “Business” and Note 13 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company's 2014 10-K.

The following table presents the reportable segment financial information:

			Optum
(in millions)	UnitedHealthcare		OptumHealth		OptumInsight		OptumRx		Optum Eliminations			Optum		Corporate and Eliminations			Consolidated
Three Months Ended June 30, 2015
Revenues - external customers:
Premiums	$	31,186	$	775	$	—	$	—	$	—		$	775	$	—		$	31,961
Services	1,715		579		542		29		—			1,150		—			2,865
Products	1		11		16		1,195		—			1,222		—			1,223
Total revenues - external customers	32,902		1,365		558		1,224		—			3,147		—			36,049
Total revenues - intersegment	—		2,031		851		7,688		(172		)	10,398		(10,398		)	—
Investment and other income	171		42		—		1		—			43		—			214
Total revenues	$	33,073	$	3,438	$	1,409	$	8,913	$	(172	)	$	13,588	$	(10,398	)	$	36,263
Earnings from operations	$	2,031	$	253	$	271	$	340	$	—		$	864	$	—		$	2,895
Interest expense	—		—		—		—		—			—		(151		)	(151		)
Earnings before income taxes	$	2,031	$	253	$	271	$	340	$	—		$	864	$	(151	)	$	2,744
Three Months Ended June 30, 2014
Revenues - external customers:
Premiums	$	28,213	$	627	$	—	$	—	$	—		$	627	$	—		$	28,840
Services	1,646		242		532		27		—			801		—			2,447
Products	1		4		14		1,018		—			1,036		—			1,037
Total revenues - external customers	29,860		873		546		1,045		—			2,464		—			32,324
Total revenues - intersegment	—		1,674		697		6,955		(115		)	9,211		(9,211		)	—
Investment and other income	211		39		—		—		—			39		—			250
Total revenues	$	30,071	$	2,586	$	1,243	$	8,000	$	(115	)	$	11,714	$	(9,211	)	$	32,574
Earnings from operations	$	1,824	$	224	$	213	$	291	$	—		$	728	$	—		$	2,552
Interest expense	—		—		—		—		—			—		(155		)	(155		)
Earnings before income taxes	$	1,824	$	224	$	213	$	291	$	—		$	728	$	(155	)	$	2,397

			Optum
(in millions)	UnitedHealthcare		OptumHealth		OptumInsight		OptumRx		Optum Eliminations			Optum		Corporate and Eliminations			Consolidated
Six Months Ended June 30, 2015
Revenues - external customers:
Premiums	$	62,091	$	1,544	$	—	$	—	$	—		$	1,544	$	—		$	63,635
Services	3,318		1,100		1,101		52		—			2,253		—			5,571
Products	1		16		36		2,400		—			2,452		—			2,453
Total revenues - external customers	65,410		2,660		1,137		2,452		—			6,249		—			71,659
Total revenues - intersegment	—		3,994		1,662		14,755		(331		)	20,080		(20,080		)	—
Investment and other income	286		73		—		1		—			74		—			360
Total revenues	$	65,696	$	6,727	$	2,799	$	17,208	$	(331	)	$	26,403	$	(20,080	)	$	72,019
Earnings from operations	$	3,929	$	487	$	493	$	626	$	—		$	1,606	$	—		$	5,535
Interest expense	—		—		—		—		—			—		(301		)	(301		)
Earnings before income taxes	$	3,929	$	487	$	493	$	626	$	—		$	1,606	$	(301	)	$	5,234
Six Months Ended June 30, 2014
Revenues - external customers:
Premiums	$	55,724	$	1,231	$	—	$	—	$	—		$	1,231	$	—		$	56,955
Services	3,232		505		1,057		57		—			1,619		—			4,851
Products	2		11		40		1,982		—			2,033		—			2,035
Total revenues - external customers	58,958		1,747		1,097		2,039		—			4,883		—			63,841
Total revenues - intersegment	—		3,345		1,393		13,419		(230		)	17,927		(17,927		)	—
Investment and other income	367		74		—		—		—			74		—			441
Total revenues	$	59,325	$	5,166	$	2,490	$	15,458	$	(230	)	$	22,884	$	(17,927	)	$	64,282
Earnings from operations	$	3,228	$	435	$	410	$	533	$	—		$	1,378	$	—		$	4,606
Interest expense	—		—		—		—		—			—		(315		)	(315		)
Earnings before income taxes	$	3,228	$	435	$	410	$	533	$	—		$	1,378	$	(315	)	$	4,291

XML

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Premiums	$ 31,961	$ 28,840	$ 63,635	$ 56,955
Services	2,865	2,447	5,571	4,851
Products	1,223	1,037	2,453	2,035
Investment and other income	214	250	360	441
Total revenues	36,263	32,574	72,019	64,282
Operating costs:
Medical costs	26,026	23,523	51,715	46,731
Operating costs	5,852	5,206	11,801	10,400
Cost of products sold	1,111	929	2,211	1,821
Depreciation and amortization	379	364	757	724
Total operating costs	33,368	30,022	66,484	59,676
Earnings from operations	2,895	2,552	5,535	4,606
Interest expense	(151)	(155)	(301)	(315)
Earnings before income taxes	2,744	2,397	5,234	4,291
Provision for income taxes	(1,159)	(989)	(2,236)	(1,784)
Net earnings	$ 1,585	$ 1,408	$ 2,998	$ 2,507
Earnings per common share:
Basic	$ 1.66	$ 1.44	$ 3.15	$ 2.56
Diluted	$ 1.64	$ 1.42	$ 3.10	$ 2.52
Basic weighted-average number of common shares outstanding	952	979	953	981
Dilutive effect of common share equivalents	14	12	14	13
Diluted weighted-average number of common shares outstanding	966	991	967	994
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	8	8	8	9
Cash dividends declared per common share	$ 0.5000	$ 0.3750	$ 0.8750	$ 0.6550

XML

Medical Costs Reserve Development (Notes)

6 Months Ended

Jun. 30, 2015

Liability for Claims and Claims Adjustment Expense [Line Items]

Medical Cost Development Disclosure Text Block

Medical Costs Reserve Development

The following table provides details of the Company's medical cost reserve development:

	Three Months Ended June 30,					Six Months Ended June 30,
(in millions)	2015			2014		2015		2014
Related to Prior Years	$	(10	)	$	40	$	130	$	260
Related to Current Year	100			90		N/A		N/A

In the three and six months ended June 30, 2015 and 2014, the medical cost reserve development was driven by a number of individual factors that were not material.

XML

Medicare Part D Pharmacy Benefits (Notes)

6 Months Ended

Jun. 30, 2015

Condensed Balance Sheet Statements, Captions [Line Items]

Medicare Part D Pharmacy Benefits Contract [Text Block]

Medicare Part D Pharmacy Benefits

The Condensed Consolidated Balance Sheets include the following amounts associated with the Medicare Part D program:

	June 30, 2015						December 31, 2014
(in millions)	Subsidies		Drug Discount		Risk-Share		Subsidies		Drug Discount		Risk-Share
Other current receivables	$	1,776	$	266	$	20	$	1,801	$	719	$	20
Other policy liabilities	—		164		—		—		302		—

See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on Medicare Part D.

XML

Medical Costs Reserve Development (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]

The following table provides details of the Company's medical cost reserve development:

	Three Months Ended June 30,					Six Months Ended June 30,
(in millions)	2015			2014		2015		2014
Related to Prior Years	$	(10	)	$	40	$	130	$	260
Related to Current Year	100			90		N/A		N/A

XML

Basis of Presentation (Policies)

6 Months Ended

Jun. 30, 2015

Basis of presentation [Abstract]

Basis of Accounting, Policy [Policy Text Block]

UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health and well-being company dedicated to helping people live healthier lives and making the health system work better for everyone. Through its diversified family of businesses, the Company leverages core competencies in advanced, enabling technology; health care data, information and intelligence; and clinical care management and coordination to help meet the demands of the health system. The Company offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.

The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC (2014 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and revenues, valuation and impairment analysis of goodwill and other intangible assets, estimates of other policy liabilities and other current receivables, valuations of certain investments, and estimates and judgments related to income taxes and contingent liabilities. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.

New Accounting Pronouncements, Policy [Policy Text Block]

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09). ASU 2014-09 will supersede existing revenue recognition standards with a single model unless those contracts are within the scope of other standards (e.g., an insurance entity’s insurance contracts). The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies can adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. In July 2015, the FASB approved the deferral of ASU 2014-09 for one year and it is effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption at the original effective date, interim and annual periods beginning after December 15, 2016, will be permitted. The Company is currently evaluating the effect of the new revenue recognition guidance.

XML

Shareholders' Equity (Notes)

6 Months Ended

Jun. 30, 2015

Stockholders' Equity Note Disclosure [Text Block]

Shareholders' Equity

Share Repurchase Program

Under its Board of Directors’ authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company’s capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time in open market purchases or other types of transactions (including prepaid or structured repurchase programs), subject to certain Board restrictions. During the six months ended June 30, 2015, the Company repurchased 9 million shares at an average price of $111.56 per share and an aggregate cost of $953 million. As of June 30, 2015, the Company had Board authorization to purchase up to 63 million shares of its common stock.

Dividends

In June 2015, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to equal an annual dividend rate of $2.00 per share compared to the annual dividend rate of $1.50 per share, which the Company had paid since June 2014. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

The following table provides details of the Company’s 2015 dividend payments:

Payment Date	Amount per Share		Total Amount Paid
			(in millions)
March 24, 2015	$	0.3750	$	357
June 24, 2015	0.5000		476

XML

Health Insurance Industry Tax (Notes)

6 Months Ended

Jun. 30, 2015

Health Insurance Industry Tax [Line Items]

Health Insurance Industry Tax [Text Block]

Health Insurance Industry Tax

The Patient Protection and Affordable Care Act and a reconciliation measure, the Health Care and Education Reconciliation Act of 2010 (together, Health Reform Legislation) includes an annual, nondeductible insurance industry tax (Health Insurance Industry Tax). As of June 30, 2015, the liability recorded in accounts payable and accrued liabilities related to the Health Insurance Industry Tax was $1.8 billion. The corresponding deferred cost recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets was $900 million. There was no liability or asset related to the Health Insurance Industry Tax recorded as of December 31, 2014 as the Health Insurance Industry Tax was paid in September 2014 and the asset was fully expensed by year end. See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on the Health Insurance Industry Tax.

XML

Commercial Paper and Long-Term Debt (Notes)

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Commercial Paper and Long-Term Debt [Text Block]

Commercial Paper and Long-Term Debt

Commercial paper and senior unsecured long-term debt consisted of the following:

	June 30, 2015						December 31, 2014
(in millions, except percentages)	Par Value		Carrying Value		Fair Value		Par Value		Carrying Value		Fair Value
Commercial paper	$	1,407	$	1,407	$	1,407	$	321	$	321	$	321
4.875% notes due March 2015 (a)	—		—		—		416		419		419
0.850% notes due October 2015 (a)	625		625		625		625		625		627
5.375% notes due March 2016 (a)	601		614		620		601		623		634
1.875% notes due November 2016 (a)	400		399		405		400		397		406
5.360% notes due November 2016	95		95		101		95		95		103
6.000% notes due June 2017 (a)	441		463		480		441		466		489
1.400% notes due October 2017 (a)	625		621		626		625		616		624
6.000% notes due November 2017 (a)	156		163		174		156		164		175
1.400% notes due December 2017 (a)	750		750		749		750		745		749
6.000% notes due February 2018 (a)	1,100		1,111		1,223		1,100		1,106		1,238
1.625% notes due March 2019 (a)	500		499		494		500		496		493
2.300% notes due December 2019 (a)	500		499		501		500		496		502
3.875% notes due October 2020 (a)	450		451		481		450		450		477
4.700% notes due February 2021 (a)	400		413		441		400		413		450
3.375% notes due November 2021 (a)	500		495		514		500		496		519
2.875% notes due December 2021 (a)	750		747		750		750		748		759
2.875% notes due March 2022 (a)	1,100		1,043		1,068		1,100		1,042		1,104
0.000% notes due November 2022	15		10		11		15		10		11
2.750% notes due February 2023 (a)	625		602		598		625		604		613
2.875% notes due March 2023 (a)	750		771		722		750		777		745
5.800% notes due March 2036	850		845		988		850		845		1,052
6.500% notes due June 2037	500		495		631		500		495		670
6.625% notes due November 2037	650		646		833		650		646		888
6.875% notes due February 2038	1,100		1,085		1,447		1,100		1,085		1,544
5.700% notes due October 2040	300		298		351		300		298		378
5.950% notes due February 2041	350		348		417		350		348		455
4.625% notes due November 2041	600		593		599		600		593		646
4.375% notes due March 2042	502		486		487		502		486		536
3.950% notes due October 2042	625		612		565		625		611		621
4.250% notes due March 2043	750		740		709		750		740		786
Total commercial paper and long-term debt	$	18,017	$	17,926	$	19,017	$	17,347	$	17,256	$	19,034

(a) Fixed-rate debt instruments hedged with interest rate swap contracts. See below for more information on the Company’s interest rate swaps.

The Company’s long-term debt obligations also included $145 million and $150 million of other financing obligations, of which $47 million and $34 million were current as of June 30, 2015 and December 31, 2014, respectively.

Commercial Paper and Bank Credit Facilities

Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of June 30, 2015, the Company’s outstanding commercial paper had a weighted-average annual interest rate of 0.3%.

The Company has $3.0 billion five-year and $1.0 billion 364-day revolving bank credit facilities with 23 banks, which mature in November 2019 and November 2015, respectively. The Company also has a $2.0 billion 364-day revolving bank credit facility with 22 banks maturing in April 2016. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. In addition, the Company has a $1.5 billion delayed draw term loan to fund the Catamaran acquisition. As of June 30, 2015, no amounts had been drawn on any of the bank credit facilities or the term loan. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities and the term loan as of June 30, 2015, annual interest rates would have ranged from 1.0% to 1.3%.

July 2015 Debt Issuance

In July 2015, the Company issued commercial paper and senior unsecured notes and drew on its delayed draw term loan. The proceeds of these debt issuances were used to fund the Catamaran acquisition. For more detail on the Catamaran acquisition see Note 1 of the Notes to the Condensed Consolidated Financial Statements.

(in millions, except percentages)	Par Value
Floating rate notes due January 2017	$	750
1.450% notes due July 2017	750
1.900% notes due July 2018	1,500
2.700% notes due July 2020	1,500
3.350% notes due July 2022	1,000
3.750% notes due July 2025	2,000
4.625% notes due July 2035	1,000
4.750% notes due July 2045	2,000
Total July 2015 Issuance	$	10,500
Delayed draw term loan	$	1,500
Commercial paper	$	2,400

Debt Covenants

The Company’s bank credit facilities contain various covenants including requiring the Company to maintain a debt to debt-plus-equity ratio of not more than 50%. The Company was in compliance with its debt covenants as of June 30, 2015.

Interest Rate Swap Contracts

The Company uses interest rate swap contracts to convert a portion of its interest rate exposure from fixed rates to floating rates to more closely align interest expense with interest income received on its variable rate financial assets. The floating rates are benchmarked to LIBOR. The swaps are designated as fair value hedges on the Company’s fixed-rate debt. Since the critical terms of the swaps match those of the debt being hedged, they are considered to be highly effective hedges and all changes in the fair values of the swaps are recorded as adjustments to the carrying value of the related debt with no net impact recorded on the Condensed Consolidated Statements of Operations. Both the hedge fair value changes and the offsetting debt adjustments are recorded in interest expense on the Condensed Consolidated Statements of Operations. The following table summarizes the location and fair value of the interest rate swap fair value hedges on the Company’s Condensed Consolidated Balance Sheet:

Type of Fair Value Hedge	Notional Amount		Fair Value		Balance Sheet Location
	(in billions)		(in millions)
June 30, 2015
Interest rate swap contracts	$	10.3	54		Other assets
			33		Other liabilities
December 31, 2014
Interest rate swap contracts	$	10.7	$	62	Other assets
			55		Other liabilities

The following table provides a summary of the effect of changes in fair value of fair value hedges on the Company’s Condensed Consolidated Statements of Operations:

	Three Months Ended June 30,						Six Months Ended  June 30,
(in millions)	2015			2014			2015			2014
Hedge - interest rate swap (loss) gain recognized in interest expense	$	(208	)	$	67		$	14		$	133
Hedged item - long-term debt gain (loss) recognized in interest expense	208			(67		)	(14		)	(133		)
Net impact on the Company’s Condensed Consolidated Statements of Operations	$	—		$	—		$	—		$	—

XML

Share-Based Compensation (Notes)

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

In June 2015, the Company’s shareholders approved an amendment to the 2011 Stock Incentive Plan (Plan). The approved amendment increased the number of shares authorized for issuance under the Plan by 70 million and removed the limit in the Plan for shares other than options and stock-settled stock appreciation rights (SARs) that can be awarded. The Company’s outstanding share-based awards consist mainly of nonqualified stock options, SARs and restricted stock and restricted stock units (collectively, restricted shares). As of June 30, 2015, the Company had 85 million shares available for future grants of share-based awards under its share-based compensation plan.

Stock Options and SARs

Stock option and SAR activity for the six months ended June 30, 2015 is summarized in the table below:

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life	Aggregate Intrinsic Value
	(in millions)				(in years)	(in millions)
Outstanding at beginning of period	33		$	53
Granted	8		109
Exercised	(6	)	52
Outstanding at end of period	35		66		6.2	$	1,971
Exercisable at end of period	18		47		3.7	1,335
Vested and expected to vest, end of period	34		66		6.1	1,933

Restricted Shares

Restricted share activity for the six months ended June 30, 2015 is summarized in the table below:

(shares in millions)	Shares		Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period	9		$	61
Granted	2		109
Vested	(4	)	57
Nonvested at end of period	7		79

Other Share-Based Compensation Data

(in millions, except per share amounts)	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Stock Options and SARs
Weighted-average grant date fair value of shares granted, per share	$	21	$	19	$	23	$	22
Total intrinsic value of stock options and SARs exercised	107		74		328		286
Restricted Shares
Weighted-average grant date fair value of shares granted, per share	118		80		109		70
Total fair value of restricted shares vested	12		9		407		423
Share-Based Compensation Items
Share-based compensation expense, before tax	86		83		211		188
Share-based compensation expense, net of tax effects	76		71		177		157
Income tax benefit realized from share-based award exercises	36		24		174		143

(in millions, except years)	June 30, 2015
Unrecognized compensation expense related to share awards	$	551
Weighted-average years to recognize compensation expense	1.4

Share-Based Compensation Recognition and Estimates

The principal assumptions the Company used in calculating grant-date fair value for stock options and SARs were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2015	2014	2015	2014
Risk-free interest rate	1.7%	1.8%	1.6% - 1.7%	1.7% - 1.8%
Expected volatility	22.5%	31.7%	22.5% - 24.1%	31.7% - 39.6%
Expected dividend yield	1.7%	1.9%	1.4% - 1.7%	1.6% - 1.9%
Forfeiture rate	5.0%	5.0%	5.0%	5.0%
Expected life in years	5.6	5.4	5.6 - 6.1	5.4

XML

Investments (Net Realized Gains) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Schedule of Available-for-sale Securities [Line Items]
Income tax effect (included in Provision for Income Taxes on the Consolidated Statements of Operations)	$ (1,159)	$ (989)	$ (2,236)	$ (1,784)
Reclassification out of Accumulated Other Comprehensive Income [Member]
Schedule of Available-for-sale Securities [Line Items]
Total OTTI	(3)	(4)	(4)	(7)
Portion of loss recognized in other comprehensive income	0	0	0	0
Net OTTI recognized in earnings	(3)	(4)	(4)	(7)
Gross realized losses from sales	(5)	(29)	(11)	(39)
Gross realized gains from sales	76	140	86	199
Net realized gains (included in investment and other income on the Consolidated Statements of Operations)	68	107	71	153
Income tax effect (included in Provision for Income Taxes on the Consolidated Statements of Operations)	(25)	(39)	(26)	(56)
Realized gains, net of taxes	$ 43	$ 68	$ 45	$ 97

XML

Share-based Compensation Narrative (Details) - Jun. 30, 2015 - 2011 Stock Incentive Plan [Member] - shares shares in Millions	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	70
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	85

XML

Fair Value (Tables)

6 Months Ended

Jun. 30, 2015

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block]

(in millions)	Quoted Prices in Active Markets (Level 1)			Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)			Total Fair and Carrying Value
June 30, 2015
Cash and cash equivalents	$	7,754		$	133		$	—		$	7,887
Debt securities - available-for-sale:
U.S. government and agency obligations	1,650			211			—			1,861
State and municipal obligations	—			6,306			—			6,306
Corporate obligations	12			7,609			78			7,699
U.S. agency mortgage-backed securities	—			2,102			—			2,102
Non-U.S. agency mortgage-backed securities	—			834			6			840
Total debt securities - available-for-sale	1,662			17,062			84			18,808
Equity securities - available-for-sale	1,226			12			319			1,557
Interest rate swap assets	—			54			—			54
Total assets at fair value	$	10,642		$	17,261		$	403		$	28,306
Percentage of total assets at fair value	38		%	61		%	1		%	100		%
Interest rate swap liabilities	$	—		$	33		$	—		$	33
December 31, 2014
Cash and cash equivalents	$	7,472		$	23		$	—		$	7,495
Debt securities - available-for-sale:
U.S. government and agency obligations	1,427			193			—			1,620
State and municipal obligations	—			6,668			—			6,668
Corporate obligations	2			7,257			68			7,327
U.S. agency mortgage-backed securities	—			2,056			—			2,056
Non-U.S. agency mortgage-backed securities	—			874			6			880
Total debt securities - available-for-sale	1,429			17,048			74			18,551
Equity securities - available-for-sale	1,200			12			310			1,522
Interest rate swap assets	—			62			—			62
Total assets at fair value	$	10,101		$	17,145		$	384		$	27,630
Percentage of total assets at fair value	37		%	62		%	1		%	100		%
Interest rate swap liabilities	$	—		$	55		$	—		$	55

Fair Value Measurements, Nonrecurring [Table Text Block]

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:

(in millions)	Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)		Total Fair Value		Total Carrying Value
June 30, 2015
Debt securities - held-to-maturity:
U.S. government and agency obligations	$	185	$	—	$	—	$	185	$	182
State and municipal obligations	—		—		15		15		15
Corporate obligations	92		10		247		349		349
Total debt securities - held-to-maturity	$	277	$	10	$	262	$	549	$	546
Other assets	$	—	$	473	$	—	$	473	$	472
Long-term debt and other financing obligations	$	—	$	17,755	$	—	$	17,755	$	16,664
December 31, 2014
Debt securities - held-to-maturity:
U.S. government and agency obligations	$	180	$	—	$	—	$	180	$	178
State and municipal obligations	—		—		19		19		19
Corporate obligations	46		10		242		298		298
Total debt securities - held-to-maturity	$	226	$	10	$	261	$	497	$	495
Other assets	$	—	$	478	$	—	$	478	$	484
Long-term debt and other financing obligations	$	—	$	18,863	$	—	$	18,863	$	17,085

Reconciliation of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs [Table Text Block]

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level 3 inputs is as follows:

	Three Months Ended									Six Months Ended
(in millions)	Debt Securities			Equity Securities			Total			Debt Securities			Equity Securities			Total
June 30, 2015
Balance at beginning of period	$	79		$	309		$	388		$	74		$	310		$	384
Purchases	6			10			16			10			14			24
Sales	(2		)	(13		)	(15		)	(2		)	(14		)	(16		)
Net unrealized gains (losses) in accumulated other comprehensive income	1			—			1			2			(5		)	(3		)
Net realized gains in investment and other income	—			13			13			—			14			14
Balance at end of period	$	84		$	319		$	403		$	84		$	319		$	403
June 30, 2014
Balance at beginning of period	$	46		$	313		$	359		$	42		$	269		$	311
Purchases	10			6			16			13			50			63
Sales	—			(147		)	(147		)	—			(151		)	(151		)
Net unrealized gains in accumulated other comprehensive income	1			6			7			2			10			12
Net realized gains in investment and other income	—			124			124			—			124			124
Balance at end of period	$	57		$	302		$	359		$	57		$	302		$	359

Fair Value Inputs, Assets, Quantitative Information [Table Text Block]

The following table presents quantitative information regarding unobservable inputs that were significant to the valuation of assets measured at fair value on a recurring basis using Level 3 inputs:

					Range
(in millions)	Fair Value		Valuation Technique	Unobservable Input	Low	High
June 30, 2015
Equity securities - available-for-sale
Venture capital portfolios	$	268	Market approach - comparable companies	Revenue multiple	1.0	5.0
				EBITDAmultiple	8.0	10.0
	51		Market approach - recent transactions	Inactive market transactions	N/A	N/A
Total equity securities      available-for-sale	$	319

AARP Program [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block]

The following table presents fair value information about the AARP Program-related financial assets and liabilities:

(in millions)	Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Total Fair and Carrying Value
June 30, 2015
Cash and cash equivalents	$	205	$	—	$	205
Debt securities:
U.S. government and agency obligations	431		164		595
State and municipal obligations	—		96		96
Corporate obligations	—		1,287		1,287
U.S. agency mortgage-backed securities	—		400		400
Non-U.S. agency mortgage-backed securities	—		195		195
Total debt securities	431		2,142		2,573
Other investments	—		85		85
Total assets at fair value	$	636	$	2,227	$	2,863
Other liabilities	$	4	$	6	$	10
December 31, 2014
Cash and cash equivalents	$	415	$	—	$	415
Debt securities:
U.S. government and agency obligations	409		245		654
State and municipal obligations	—		95		95
Corporate obligations	—		1,200		1,200
U.S. agency mortgage-backed securities	—		340		340
Non-U.S. agency mortgage-backed securities	—		177		177
Total debt securities	409		2,057		2,466
Other investments	—		81		81
Total assets at fair value	$	824	$	2,138	$	2,962
Other liabilities	$	5	$	13	$	18

XML

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option and SAR Activity [Table Text Block]

Stock option and SAR activity for the six months ended June 30, 2015 is summarized in the table below:

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life	Aggregate Intrinsic Value
	(in millions)				(in years)	(in millions)
Outstanding at beginning of period	33		$	53
Granted	8		109
Exercised	(6	)	52
Outstanding at end of period	35		66		6.2	$	1,971
Exercisable at end of period	18		47		3.7	1,335
Vested and expected to vest, end of period	34		66		6.1	1,933

Restricted Share Activity [Table Text Block]

Restricted share activity for the six months ended June 30, 2015 is summarized in the table below:

(shares in millions)	Shares		Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period	9		$	61
Granted	2		109
Vested	(4	)	57
Nonvested at end of period	7		79

Other Share-Based Compensation Data [Table Text Block]

Other Share-Based Compensation Data

(in millions, except per share amounts)	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Stock Options and SARs
Weighted-average grant date fair value of shares granted, per share	$	21	$	19	$	23	$	22
Total intrinsic value of stock options and SARs exercised	107		74		328		286
Restricted Shares
Weighted-average grant date fair value of shares granted, per share	118		80		109		70
Total fair value of restricted shares vested	12		9		407		423
Share-Based Compensation Items
Share-based compensation expense, before tax	86		83		211		188
Share-based compensation expense, net of tax effects	76		71		177		157
Income tax benefit realized from share-based award exercises	36		24		174		143

(in millions, except years)	June 30, 2015
Unrecognized compensation expense related to share awards	$	551
Weighted-average years to recognize compensation expense	1.4

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The principal assumptions the Company used in calculating grant-date fair value for stock options and SARs were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2015	2014	2015	2014
Risk-free interest rate	1.7%	1.8%	1.6% - 1.7%	1.7% - 1.8%
Expected volatility	22.5%	31.7%	22.5% - 24.1%	31.7% - 39.6%
Expected dividend yield	1.7%	1.9%	1.4% - 1.7%	1.6% - 1.9%
Forfeiture rate	5.0%	5.0%	5.0%	5.0%
Expected life in years	5.6	5.4	5.6 - 6.1	5.4

XML

Shareholders' Equity (Details) - Equity Component [Domain] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Shares Repurchased During Period	9
Shares Repurchased, Average Cost Per Share	$ 111.56
Common share repurchases	$ 953	$ 1,937
Share Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	63
Cash Dividend Annual Rate Per Share	$ 2.00	$ 1.50

XML

Medicare Part D Pharmacy Benefits Medicare Part D Pharmacy Benefits Schedule of Receivables and Payables (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Other current receivables	$ 6,160	$ 5,498
Other policy liabilities	6,772	5,965
CMS Subsidies [Member]
Other current receivables	1,776	1,801
Other policy liabilities	0	0
Drug Discount [Member]
Other current receivables	266	719
Other policy liabilities	164	302
Risk-Share [Member]
Other current receivables	20	20
Other policy liabilities	$ 0	$ 0

XML

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net earnings	$ 1,585	$ 1,408	$ 2,998	$ 2,507
Other comprehensive (loss) income:
Gross unrealized (losses) gains on investment securities during the period	(222)	314	(117)	480
Income tax effect	80	(114)	43	(175)
Total unrealized (losses) gains, net of tax	(142)	200	(74)	305
Gross reclassification adjustment for net realized gains included in net earnings	(68)	(107)	(71)	(153)
Income tax effect	25	39	26	56
Total reclassification adjustment, net of tax	(43)	(68)	(45)	(97)
Total foreign currency translation gains (losses)	163	151	(796)	410
Other comprehensive (loss) income	(22)	283	(915)	618
Comprehensive income	$ 1,563	$ 1,691	$ 2,083	$ 3,125

XML

Fair Value (Notes)

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value [Text Block]

Fair Value

Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.

For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the 2014 10-K.

The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets excluding assets and liabilities, related to a Supplemental Health Insurance Program (AARP Program), which are presented in a separate table below:

(in millions)	Quoted Prices in Active Markets (Level 1)			Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)			Total Fair and Carrying Value
June 30, 2015
Cash and cash equivalents	$	7,754		$	133		$	—		$	7,887
Debt securities - available-for-sale:
U.S. government and agency obligations	1,650			211			—			1,861
State and municipal obligations	—			6,306			—			6,306
Corporate obligations	12			7,609			78			7,699
U.S. agency mortgage-backed securities	—			2,102			—			2,102
Non-U.S. agency mortgage-backed securities	—			834			6			840
Total debt securities - available-for-sale	1,662			17,062			84			18,808
Equity securities - available-for-sale	1,226			12			319			1,557
Interest rate swap assets	—			54			—			54
Total assets at fair value	$	10,642		$	17,261		$	403		$	28,306
Percentage of total assets at fair value	38		%	61		%	1		%	100		%
Interest rate swap liabilities	$	—		$	33		$	—		$	33
December 31, 2014
Cash and cash equivalents	$	7,472		$	23		$	—		$	7,495
Debt securities - available-for-sale:
U.S. government and agency obligations	1,427			193			—			1,620
State and municipal obligations	—			6,668			—			6,668
Corporate obligations	2			7,257			68			7,327
U.S. agency mortgage-backed securities	—			2,056			—			2,056
Non-U.S. agency mortgage-backed securities	—			874			6			880
Total debt securities - available-for-sale	1,429			17,048			74			18,551
Equity securities - available-for-sale	1,200			12			310			1,522
Interest rate swap assets	—			62			—			62
Total assets at fair value	$	10,101		$	17,145		$	384		$	27,630
Percentage of total assets at fair value	37		%	62		%	1		%	100		%
Interest rate swap liabilities	$	—		$	55		$	—		$	55

Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs; there were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the six months ended June 30, 2015 or 2014.

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:

(in millions)	Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)		Total Fair Value		Total Carrying Value
June 30, 2015
Debt securities - held-to-maturity:
U.S. government and agency obligations	$	185	$	—	$	—	$	185	$	182
State and municipal obligations	—		—		15		15		15
Corporate obligations	92		10		247		349		349
Total debt securities - held-to-maturity	$	277	$	10	$	262	$	549	$	546
Other assets	$	—	$	473	$	—	$	473	$	472
Long-term debt and other financing obligations	$	—	$	17,755	$	—	$	17,755	$	16,664
December 31, 2014
Debt securities - held-to-maturity:
U.S. government and agency obligations	$	180	$	—	$	—	$	180	$	178
State and municipal obligations	—		—		19		19		19
Corporate obligations	46		10		242		298		298
Total debt securities - held-to-maturity	$	226	$	10	$	261	$	497	$	495
Other assets	$	—	$	478	$	—	$	478	$	484
Long-term debt and other financing obligations	$	—	$	18,863	$	—	$	18,863	$	17,085

Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the six months ended June 30, 2015 or 2014.

The carrying amounts reported on the Condensed Consolidated Balance Sheets for other current financial assets and liabilities approximate fair value because of their short-term nature. These assets and liabilities are not listed in the table above.

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level 3 inputs is as follows:

	Three Months Ended									Six Months Ended
(in millions)	Debt Securities			Equity Securities			Total			Debt Securities			Equity Securities			Total
June 30, 2015
Balance at beginning of period	$	79		$	309		$	388		$	74		$	310		$	384
Purchases	6			10			16			10			14			24
Sales	(2		)	(13		)	(15		)	(2		)	(14		)	(16		)
Net unrealized gains (losses) in accumulated other comprehensive income	1			—			1			2			(5		)	(3		)
Net realized gains in investment and other income	—			13			13			—			14			14
Balance at end of period	$	84		$	319		$	403		$	84		$	319		$	403
June 30, 2014
Balance at beginning of period	$	46		$	313		$	359		$	42		$	269		$	311
Purchases	10			6			16			13			50			63
Sales	—			(147		)	(147		)	—			(151		)	(151		)
Net unrealized gains in accumulated other comprehensive income	1			6			7			2			10			12
Net realized gains in investment and other income	—			124			124			—			124			124
Balance at end of period	$	57		$	302		$	359		$	57		$	302		$	359

The following table presents quantitative information regarding unobservable inputs that were significant to the valuation of assets measured at fair value on a recurring basis using Level 3 inputs:

					Range
(in millions)	Fair Value		Valuation Technique	Unobservable Input	Low	High
June 30, 2015
Equity securities - available-for-sale
Venture capital portfolios	$	268	Market approach - comparable companies	Revenue multiple	1.0	5.0
				EBITDAmultiple	8.0	10.0
	51		Market approach - recent transactions	Inactive market transactions	N/A	N/A
Total equity securities      available-for-sale	$	319

Also included in the Company’s assets measured at fair value on a recurring basis using Level 3 inputs were $84 million of available-for-sale debt securities as of June 30, 2015, which were not significant.

The Company elected to measure the entirety of the AARP Program assets under management at fair value pursuant to the fair value option. See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on the AARP Program. The following table presents fair value information about the AARP Program-related financial assets and liabilities:

(in millions)	Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Total Fair and Carrying Value
June 30, 2015
Cash and cash equivalents	$	205	$	—	$	205
Debt securities:
U.S. government and agency obligations	431		164		595
State and municipal obligations	—		96		96
Corporate obligations	—		1,287		1,287
U.S. agency mortgage-backed securities	—		400		400
Non-U.S. agency mortgage-backed securities	—		195		195
Total debt securities	431		2,142		2,573
Other investments	—		85		85
Total assets at fair value	$	636	$	2,227	$	2,863
Other liabilities	$	4	$	6	$	10
December 31, 2014
Cash and cash equivalents	$	415	$	—	$	415
Debt securities:
U.S. government and agency obligations	409		245		654
State and municipal obligations	—		95		95
Corporate obligations	—		1,200		1,200
U.S. agency mortgage-backed securities	—		340		340
Non-U.S. agency mortgage-backed securities	—		177		177
Total debt securities	409		2,057		2,466
Other investments	—		81		81
Total assets at fair value	$	824	$	2,138	$	2,962
Other liabilities	$	5	$	13	$	18

XML

Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement [Line Items]
Premiums, revenues - external customers	$ 31,961	$ 28,840	$ 63,635	$ 56,955
Services, revenues - external customers	2,865	2,447	5,571	4,851
Products, revenues - external customers	1,223	1,037	2,453	2,035
Investment and other income	214	250	360	441
Total revenues	36,263	32,574	72,019	64,282
Earnings from operations	2,895	2,552	5,535	4,606
Interest expense	(151)	(155)	(301)	(315)
Earnings before income taxes	2,744	2,397	5,234	4,291
Optum [Member]
Statement [Line Items]
Investment and other income	43	39	74	74
Total revenues	13,588	11,714	26,403	22,884
Earnings from operations	864	728	1,606	1,378
Interest expense	0	0	0	0
Earnings before income taxes	864	728	1,606	1,378
External Customers [Member]
Statement [Line Items]
Premiums, revenues - external customers	31,961	28,840	63,635	56,955
Services, revenues - external customers	2,865	2,447	5,571	4,851
Products, revenues - external customers	1,223	1,037	2,453	2,035
Total revenues	36,049	32,324	71,659	63,841
External Customers [Member] | Optum [Member]
Statement [Line Items]
Premiums, revenues - external customers	775	627	1,544	1,231
Services, revenues - external customers	1,150	801	2,253	1,619
Products, revenues - external customers	1,222	1,036	2,452	2,033
Total revenues	3,147	2,464	6,249	4,883
Intersegment [Member]
Statement [Line Items]
Total revenues	0	0	0	0
Intersegment [Member] | Optum [Member]
Statement [Line Items]
Total revenues	10,398	9,211	20,080	17,927
Operating Segments [Member] | UnitedHealthcare [Member]
Statement [Line Items]
Investment and other income	171	211	286	367
Total revenues	33,073	30,071	65,696	59,325
Earnings from operations	2,031	1,824	3,929	3,228
Interest expense	0	0	0	0
Earnings before income taxes	2,031	1,824	3,929	3,228
Operating Segments [Member] | Optumhealth [Member]
Statement [Line Items]
Investment and other income	42	39	73	74
Total revenues	3,438	2,586	6,727	5,166
Earnings from operations	253	224	487	435
Interest expense	0	0	0	0
Earnings before income taxes	253	224	487	435
Operating Segments [Member] | Optuminsight [Member]
Statement [Line Items]
Investment and other income	0	0	0	0
Total revenues	1,409	1,243	2,799	2,490
Earnings from operations	271	213	493	410
Interest expense	0	0	0	0
Earnings before income taxes	271	213	493	410
Operating Segments [Member] | Optumrx [Member]
Statement [Line Items]
Investment and other income	1	0	1	0
Total revenues	8,913	8,000	17,208	15,458
Earnings from operations	340	291	626	533
Interest expense	0	0	0	0
Earnings before income taxes	340	291	626	533
Operating Segments [Member] | External Customers [Member] | UnitedHealthcare [Member]
Statement [Line Items]
Premiums, revenues - external customers	31,186	28,213	62,091	55,724
Services, revenues - external customers	1,715	1,646	3,318	3,232
Products, revenues - external customers	1	1	1	2
Total revenues	32,902	29,860	65,410	58,958
Operating Segments [Member] | External Customers [Member] | Optumhealth [Member]
Statement [Line Items]
Premiums, revenues - external customers	775	627	1,544	1,231
Services, revenues - external customers	579	242	1,100	505
Products, revenues - external customers	11	4	16	11
Total revenues	1,365	873	2,660	1,747
Operating Segments [Member] | External Customers [Member] | Optuminsight [Member]
Statement [Line Items]
Premiums, revenues - external customers	0	0	0	0
Services, revenues - external customers	542	532	1,101	1,057
Products, revenues - external customers	16	14	36	40
Total revenues	558	546	1,137	1,097
Operating Segments [Member] | External Customers [Member] | Optumrx [Member]
Statement [Line Items]
Premiums, revenues - external customers	0	0	0	0
Services, revenues - external customers	29	27	52	57
Products, revenues - external customers	1,195	1,018	2,400	1,982
Total revenues	1,224	1,045	2,452	2,039
Operating Segments [Member] | Intersegment [Member] | UnitedHealthcare [Member]
Statement [Line Items]
Total revenues	0	0	0	0
Operating Segments [Member] | Intersegment [Member] | Optumhealth [Member]
Statement [Line Items]
Total revenues	2,031	1,674	3,994	3,345
Operating Segments [Member] | Intersegment [Member] | Optuminsight [Member]
Statement [Line Items]
Total revenues	851	697	1,662	1,393
Operating Segments [Member] | Intersegment [Member] | Optumrx [Member]
Statement [Line Items]
Total revenues	7,688	6,955	14,755	13,419
Optum Eliminations [Member]
Statement [Line Items]
Investment and other income	0	0	0	0
Total revenues	(172)	(115)	(331)	(230)
Earnings from operations	0	0	0	0
Interest expense	0	0	0	0
Earnings before income taxes	0	0	0	0
Optum Eliminations [Member] | External Customers [Member]
Statement [Line Items]
Premiums, revenues - external customers	0	0	0	0
Services, revenues - external customers	0	0	0	0
Products, revenues - external customers	0	0	0	0
Total revenues	0	0	0	0
Optum Eliminations [Member] | Intersegment [Member]
Statement [Line Items]
Total revenues	(172)	(115)	(331)	(230)
Corporate and Eliminations [Member]
Statement [Line Items]
Investment and other income	0	0	0	0
Total revenues	(10,398)	(9,211)	(20,080)	(17,927)
Earnings from operations	0	0	0	0
Interest expense	(151)	(155)	(301)	(315)
Earnings before income taxes	(151)	(155)	(301)	(315)
Corporate and Eliminations [Member] | External Customers [Member]
Statement [Line Items]
Premiums, revenues - external customers	0	0	0	0
Services, revenues - external customers	0	0	0	0
Products, revenues - external customers	0	0	0	0
Total revenues	0	0	0	0
Corporate and Eliminations [Member] | Intersegment [Member]
Statement [Line Items]
Total revenues	$ (10,398)	$ (9,211)	$ (20,080)	$ (17,927)

XML

Segment Financial Information (Tables)

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Segment Financial Information [Table Text Block]

The following table presents the reportable segment financial information:

			Optum
(in millions)	UnitedHealthcare		OptumHealth		OptumInsight		OptumRx		Optum Eliminations			Optum		Corporate and Eliminations			Consolidated
Three Months Ended June 30, 2015
Revenues - external customers:
Premiums	$	31,186	$	775	$	—	$	—	$	—		$	775	$	—		$	31,961
Services	1,715		579		542		29		—			1,150		—			2,865
Products	1		11		16		1,195		—			1,222		—			1,223
Total revenues - external customers	32,902		1,365		558		1,224		—			3,147		—			36,049
Total revenues - intersegment	—		2,031		851		7,688		(172		)	10,398		(10,398		)	—
Investment and other income	171		42		—		1		—			43		—			214
Total revenues	$	33,073	$	3,438	$	1,409	$	8,913	$	(172	)	$	13,588	$	(10,398	)	$	36,263
Earnings from operations	$	2,031	$	253	$	271	$	340	$	—		$	864	$	—		$	2,895
Interest expense	—		—		—		—		—			—		(151		)	(151		)
Earnings before income taxes	$	2,031	$	253	$	271	$	340	$	—		$	864	$	(151	)	$	2,744
Three Months Ended June 30, 2014
Revenues - external customers:
Premiums	$	28,213	$	627	$	—	$	—	$	—		$	627	$	—		$	28,840
Services	1,646		242		532		27		—			801		—			2,447
Products	1		4		14		1,018		—			1,036		—			1,037
Total revenues - external customers	29,860		873		546		1,045		—			2,464		—			32,324
Total revenues - intersegment	—		1,674		697		6,955		(115		)	9,211		(9,211		)	—
Investment and other income	211		39		—		—		—			39		—			250
Total revenues	$	30,071	$	2,586	$	1,243	$	8,000	$	(115	)	$	11,714	$	(9,211	)	$	32,574
Earnings from operations	$	1,824	$	224	$	213	$	291	$	—		$	728	$	—		$	2,552
Interest expense	—		—		—		—		—			—		(155		)	(155		)
Earnings before income taxes	$	1,824	$	224	$	213	$	291	$	—		$	728	$	(155	)	$	2,397

			Optum
(in millions)	UnitedHealthcare		OptumHealth		OptumInsight		OptumRx		Optum Eliminations			Optum		Corporate and Eliminations			Consolidated
Six Months Ended June 30, 2015
Revenues - external customers:
Premiums	$	62,091	$	1,544	$	—	$	—	$	—		$	1,544	$	—		$	63,635
Services	3,318		1,100		1,101		52		—			2,253		—			5,571
Products	1		16		36		2,400		—			2,452		—			2,453
Total revenues - external customers	65,410		2,660		1,137		2,452		—			6,249		—			71,659
Total revenues - intersegment	—		3,994		1,662		14,755		(331		)	20,080		(20,080		)	—
Investment and other income	286		73		—		1		—			74		—			360
Total revenues	$	65,696	$	6,727	$	2,799	$	17,208	$	(331	)	$	26,403	$	(20,080	)	$	72,019
Earnings from operations	$	3,929	$	487	$	493	$	626	$	—		$	1,606	$	—		$	5,535
Interest expense	—		—		—		—		—			—		(301		)	(301		)
Earnings before income taxes	$	3,929	$	487	$	493	$	626	$	—		$	1,606	$	(301	)	$	5,234
Six Months Ended June 30, 2014
Revenues - external customers:
Premiums	$	55,724	$	1,231	$	—	$	—	$	—		$	1,231	$	—		$	56,955
Services	3,232		505		1,057		57		—			1,619		—			4,851
Products	2		11		40		1,982		—			2,033		—			2,035
Total revenues - external customers	58,958		1,747		1,097		2,039		—			4,883		—			63,841
Total revenues - intersegment	—		3,345		1,393		13,419		(230		)	17,927		(17,927		)	—
Investment and other income	367		74		—		—		—			74		—			441
Total revenues	$	59,325	$	5,166	$	2,490	$	15,458	$	(230	)	$	22,884	$	(17,927	)	$	64,282
Earnings from operations	$	3,228	$	435	$	410	$	533	$	—		$	1,378	$	—		$	4,606
Interest expense	—		—		—		—		—			—		(315		)	(315		)
Earnings before income taxes	$	3,228	$	435	$	410	$	533	$	—		$	1,378	$	(315	)	$	4,291

XML

Fair Value (Reconciliation of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 388	$ 359	$ 384	$ 311
Purchases	16	16	24	63
Sales	(15)	(147)	(16)	(151)
Net unrealized gains (losses) in accumulated other comprehensive income	1	7	(3)	12
Net realized losses in investment and other income	13	124	14	124
Balance at end of period	403	359	403	359
Debt Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	79	46	74	42
Purchases	6	10	10	13
Sales	(2)	0	(2)	0
Net unrealized gains (losses) in accumulated other comprehensive income	1	1	2	2
Net realized losses in investment and other income	0	0	0	0
Balance at end of period	84	57	84	57
Equity Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	309	313	310	269
Purchases	10	6	14	50
Sales	(13)	(147)	(14)	(151)
Net unrealized gains (losses) in accumulated other comprehensive income	0	6	(5)	10
Net realized losses in investment and other income	13	124	14	124
Balance at end of period	$ 319	$ 302	$ 319	$ 302

XML

Investments (Tables)

6 Months Ended

Jun. 30, 2015

Short-Term and Long-Term Investments [Table Text Block]

A summary of short-term and long-term investments by major security type is as follows:

(in millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2015
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,859	$	6	$	(4	)	$	1,861
State and municipal obligations	6,196		127		(17		)	6,306
Corporate obligations	7,654		76		(31		)	7,699
U.S. agency mortgage-backed securities	2,091		25		(14		)	2,102
Non-U.S. agency mortgage-backed securities	837		8		(5		)	840
Total debt securities - available-for-sale	18,637		242		(71		)	18,808
Equity securities - available-for-sale	1,559		36		(38		)	1,557
Debt securities - held-to-maturity:
U.S. government and agency obligations	182		3		—			185
State and municipal obligations	15		—		—			15
Corporate obligations	349		—		—			349
Total debt securities - held-to-maturity	546		3		—			549
Total investments	$	20,742	$	281	$	(109	)	$	20,914
December 31, 2014
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,614	$	7	$	(1	)	$	1,620
State and municipal obligations	6,456		217		(5		)	6,668
Corporate obligations	7,241		112		(26		)	7,327
U.S. agency mortgage-backed securities	2,022		39		(5		)	2,056
Non-U.S. agency mortgage-backed securities	872		12		(4		)	880
Total debt securities - available-for-sale	18,205		387		(41		)	18,551
Equity securities - available-for-sale	1,511		36		(25		)	1,522
Debt securities - held-to-maturity:
U.S. government and agency obligations	178		2		—			180
State and municipal obligations	19		—		—			19
Corporate obligations	298		—		—			298
Total debt securities - held-to-maturity	495		2		—			497
Total investments	$	20,211	$	425	$	(66	)	$	20,570

Fair Value of Available-for-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time that Individual Securities have been in a Continuous Unrealized Loss Position [Table Text Block]

The fair value of available-for-sale investments with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:

	Less Than 12 Months					12 Months or Greater					Total
(in millions)	Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses
June 30, 2015
Debt securities - available-for-sale:
U.S. government and agency obligations	$	529	$	(4	)	$	—	$	—		$	529	$	(4	)
State and municipal obligations	1,561		(16		)	22		(1		)	1,583		(17		)
Corporate obligations	3,126		(27		)	229		(4		)	3,355		(31		)
U.S. agency mortgage-backed securities	752		(10		)	126		(4		)	878		(14		)
Non-U.S. agency mortgage-backed securities	364		(4		)	77		(1		)	441		(5		)
Total debt securities - available-for-sale	$	6,332	$	(61	)	$	454	$	(10	)	$	6,786	$	(71	)
Equity securities - available-for-sale	$	148	$	(9	)	$	82	$	(29	)	$	230	$	(38	)
December 31, 2014
Debt securities - available-for-sale:
U.S. government and agency obligations	$	420	$	(1	)	$	—	$	—		$	420	$	(1	)
State and municipal obligations	711		(4		)	99		(1		)	810		(5		)
Corporate obligations	2,595		(17		)	464		(9		)	3,059		(26		)
U.S. agency mortgage-backed securities	—		—			272		(5		)	272		(5		)
Non-U.S. agency mortgage-backed securities	254		(2		)	114		(2		)	368		(4		)
Total debt securities - available-for-sale	$	3,980	$	(24	)	$	949	$	(17	)	$	4,929	$	(41	)
Equity securities - available-for-sale	$	107	$	(6	)	$	88	$	(19	)	$	195	$	(25	)

Net Realized Gains, Included in Investment and Other Income [Table Text Block]

Net realized gains reclassified out of accumulated other comprehensive income were from the following sources:

	Three Months Ended June 30,						Six Months Ended June 30,
(in millions)	2015			2014			2015			2014
Total OTTI	$	(3	)	$	(4	)	$	(4	)	$	(7	)
Portion of loss recognized in other comprehensive income	—			—			—			—
Net OTTI recognized in earnings	(3		)	(4		)	(4		)	(7		)
Gross realized losses from sales	(5		)	(29		)	(11		)	(39		)
Gross realized gains from sales	76			140			86			199
Net realized gains (included in investment and other income on the Condensed Consolidated Statements of Operations)	68			107			71			153
Income tax effect (included in provision for income taxes on the Condensed Consolidated Statements of Operations)	(25		)	(39		)	(26		)	(56		)
Realized gains, net of taxes	$	43		$	68		$	45		$	97

Available-for-sale Securities [Member]

Investments by Contractual Maturity [Table Text Block]

The amortized cost and fair value of available-for-sale debt securities as of June 30, 2015, by contractual maturity, were as follows:

(in millions)	Amortized Cost		Fair Value
Due in one year or less	$	2,010	$	2,014
Due after one year through five years	6,943		7,009
Due after five years through ten years	5,016		5,067
Due after ten years	1,740		1,776
U.S. agency mortgage-backed securities	2,091		2,102
Non-U.S. agency mortgage-backed securities	837		840
Total debt securities - available-for-sale	$	18,637	$	18,808

Held-to-maturity Securities [Member]

Investments by Contractual Maturity [Table Text Block]

The amortized cost and fair value of held-to-maturity debt securities as of June 30, 2015, by contractual maturity, were as follows:

(in millions)	Amortized Cost		Fair Value
Due in one year or less	$	126	$	126
Due after one year through five years	204		205
Due after five years through ten years	106		107
Due after ten years	110		111
Total debt securities - held-to-maturity	$	546	$	549